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ABSTRACT 
ISAAC S. CHAN: Hedgehog Signaling in Hepatocellular Carcinoma 
(Under the direction of Dr. Anna Mae Diehl and Dr. Albert Baldwin) 
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and one of the most 
common and deadly tumors worldwide. Most HCC cases are secondary to cirrhosis of 
the liver resulting from chronic liver injury states and dysregulated wound healing.  While 
treatment of the cancer often involves resection, high recurrence rates are common, 
suggesting that cells outside the tumor play an important role in tumorigenesis. While the 
microenvironment is a key contributor to carcinogensis, the molecular mechanisms 
underlying their involvement remain unknown.  Hedgehog (Hh) signaling has been found 
to play a critical role in liver regeneration after injury and Hh pathway activity is 
overexpressed in the pre-neoplastic and injured liver environment, leading us to 
hypothesize that it plays an essential role in the development and progression of HCC.  
This dissertation addresses the role of Hh signaling in HCCarcinogenesis and, 
specifically, the liver tumor microenvironment.  Advances in this subject can lead to new 
therapeutic options for patients suffering from the burden of this disease. 
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 CHAPTER 1 
INTRODUCTION 
1.1. Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and is the third 
leading cause of cancer-related deaths worldwide.  The incidence of HCC is nearly identical 
to the number of deaths per year (Jemal, Bray et al. 2011).  In 2008, the incidence of HCC 
was estimated to be 16 cases per 100,000 individuals (Forner, Llovet et al. 2012), and has 
risen to over 700,000 cases diagnosed each year (Ferlay, Shin et al. 2010). 
 
1.1.1 – Risk factors for HCC 
The single largest risk factor for HCC is fibrosis and cirrhosis (Schuppan and Afdhal 
2008).  Patients with compensated liver cirrhosis have a 1-5% annual risk of HCC and over 
56% of patients with HCC have undiagnosed cirrhosis (Forner, Llovet et al. 2012).  Because 
all chronic liver diseases lead to cirrhosis, all are risk factors for HCC.  The most common of 
these is viral hepatitis, caused by either hepatitis B virus, accounting for over half of HCC, or 
hepatitis C virus, accounting for a third of all cases in the US (Sherman 2010).  Given the 
current positive response rates to antiviral therapy in the US, the incidence of HCC due to 
viral hepatitis is plateauing (Davis, Alter et al. 2010).  Yet unexpectedly, overall incidence 
has increased by almost 50% in the past two decades, suggesting that other factors are 
contributing to HCC development (Forner, Llovet et al. 2012).   
An emergent risk factor for HCC is non-alcoholic fatty liver disease (NAFLD).  There 
is growing evidence of a correlation between HCC, NAFLD, and NALFD-associated 
conditions, such as obesity and diabetes: The yearly incidence of HCC in NALFD patients is 
2.7% (Ascha, Hanouneh et al. 2010).  Patients with a baseline body-mass index over 40 
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have five times higher risk for HCC development and in certain studies, diabetes patients 
are 4.5 times more likely to develop HCC (Adami, Chow et al. 1996; Calle, Rodriguez et al. 
2003).  While the exact mechanism underlying NAFLD HCC carcinogenesis remains 
unknown, it is thought that steatoic changes in NAFLD induces inflammatory and wound-
healing responses that lead to cirrhosis and HCC.  Other risk factors for HCC include 
alcoholic liver disease: Compared to teetotalers, patients who regularly consume alcohol are 
3.6 times more likely to develop HCC on cirrhosis (Ascha, Hanouneh et al. 2010).  Thus, 
regardless of the etiology of the underlying liver disease, most HCCs arise from an 
established background of cirrhosis. 
 
1.1.2 – Molecular characteristics of HCC 
Analysis of HCC tumors has revealed alterations in several genes causing multiple 
genetic networks to become dysregulated, reflective of a heterogenous molecular profile.  
These genetic alterations can include somatic gene mutations linked to cell proliferation and 
cell cycle regulation.  The most frequently mutated gene in HCC is p53 and some reports 
have found it to be mutated in as many as 67% of HCCs (Coursaget, Depril et al. 1993).  
Other HCC associated gene mutations include both tumor suppressors and oncogenes such 
as p16 (Hui, Sakamoto et al. 1996), Rb (Zhang, Xu et al. 1994), Pten (Fujiwara, Hoon et al. 
2000), Met (Wang, Ferrell et al. 2001), PI3K (Lee, Soung et al. 2005), B-catenin (Ishizaki, 
Ikeda et al. 2004), and Smoothened (Sicklick, Li et al. 2006).  In addition, HCC harbors 
amplifications of Vegf (Miura, Miyazaki et al. 1997) and angiogenesis associated genes 
(Torimura, Ueno et al. 2004).  The abundance of studies identifying key drivers of HCC 
merely point to the many genetic alterations that can result in the activation and 
dysregulation of a variety signaling pathways including Wnt, Hedgehog, MTOR, and Ras.  
These dysregulated signaling pathways have been implicated in supporting abnormal 
proliferation, angiogenesis, and metastasis in HCC. 
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1.1.3 – Diagnosis and treatment of HCC 
In patients with increased risk for developing HCC (i.e. cirrhotic patients), the 
preferred methods for monitoring and diagnosis are ultrasonography (the gold standard) and 
serum alpha-fetoprotein (AFP) levels.  Sensitivity for ultrasonography imaging ranges 
between 60-80% with a specificity exceeding 90%.  However, the accuracy of AFP 
monitoring has been questioned.  The sensitivity of AFP serum monitoring is at best 66% 
(Marrero, Feng et al. 2009) and even when combined with ultrasonography, detection rates 
improve by only 8% while considerably raising the number of false positives compared to 
ultrasonography alone (Zhang and Yang 1999).  These results raise the need for the 
identification of better and more sensitive biomarkers that predict the presence of HCC.   
Once identified, HCC is staged (Pons, Varela et al. 2005) and management is based 
on tumor stage and liver function.  Management of HCC may involve ablation, resection, 
transplantation, chemoembolizastion, or chemotherapy.  Unfortunately for HCC patients, few 
randomized control trials have been run comparing different treatment options and the 
collective data are conflicting (Llovet, Di Bisceglie et al. 2008).  For early stage tumors 
(single nodules < 2 cm), first-line therapy often involves ablation, which has a 5-year survival 
of 50-70% (Cho, Kim et al. 2009).  However, ablation techniques become increasingly less 
effective as nodule size and multifocality increases.  Although hepatic resection is preferred 
treatment for noncirrhotic patients, it is estimated that only 5% of patients in the US qualify, 
and after 5 years, tumor recurrence occurs in over 70% of cases (Llovet, Schwartz et al. 
2005).  For patients with non-metastatic HCC and cirrhosis, liver transplantation is often 
curative for both, making HCC unique as the only solid tumor that can be “cured” through 
organ transplantation.  According to one study, patients with one HCC nodule smaller than 5 
cm or patients with up to three nodules of less than 3 cm treated with liver transplantation 
had four-year survival rates of 75% and less than 15% with recurrence (Mazzaferro, Regalia 
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et al. 1996).  Despite these outstanding results, liver transplantation is limited as an option 
due to the shortage of organs available for transplant (Bruix and Sherman 2011).  
Furthermore, liver transplantation is feasible in only 5% of HCC patients due to underlying 
liver disease (Rougier, Mitry et al. 2007).  Therefore, while surgical procedures are the first 
line for early stage HCC, many patients fail to qualify.   
 
Currently, no systemic chemotherapies (e.g. doxorubicin) or hormonal therapies (e.g. 
tamoxifen, flutamide) have been shown to improve overall patient survival (Lai, Wu et al. 
1988; Chao, Chan et al. 1996; Nowak, Findlay et al. 2004).  The only FDA-approved 
therapeutic agent for late stage HCC is Sorafenib, an orally administered multikinase 
inhibitor that inhibits Raf signaling, VEGF, PDGF, and c-Kit (Bruix and Sherman 2011).  
Sorafenib has been shown to significantly increase overall survival by about three months 
(10.7 months vs. 7.9 months in placebo group) (Llovet, Ricci et al. 2008).  Still, despite 
progress towards better therapies for HCC patients, more can be done.  While this section is 
not meant to be an exhaustive listing of every HCC treatment tested in clinical trials, it 
highlights the very limited treatment options that are currently offered.  There is a real 
patient-driven need for novel treatment therapies and understanding the molecular events in 
the pre-neoplastic environment leading to HCC could reveal new targets for better 
treatment. 
 
1.2. Cirrhosis: the pre-neoplastic environment  
Since the leading risk factor for HCC is fibrosis and cirrhosis, appreciating the pre-
neoplastic state of the liver is important for the prevention and treatment of HCC.  Chronic 
liver injury leads to fibrosis and cirrhosis, outcomes resulting from dysregulated (i.e., 
excessively fibrogenic) repair of liver injury.  Initially part of the normal wound healing 
process, fibrosis can accumulate and become pathologic due to sustained signals 
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associated with chronic liver injury, leading to progressive accumulation of collagen matrix 
(Figure 1.1).  As a result, liver function becomes impaired.   
Liver scar tissue is composed of extracellular matrix comprised primarily of collagen.  
While several cells in the liver can produce collagen (Sedlaczek, Jia et al. 2001), liver 
myofibroblasts (MF) are the major producers of collagen in injured livers (Friedman 2008).  
Liver MF accumulation is stimulated by various injury-associated growth factors/cytokines, 
including platelet derived growth factor (PDGF), transforming growth factor (TGF) beta, and 
Hedgehog signaling (Pinzani, Knauss et al. 1991; Okuno, Moriwaki et al. 1997; Omenetti 
and Diehl 2008).  Although different studies have shown that liver MF can be derived from 
many different sources including portal fibroblasts (Knittel, Kobold et al. 1999), hepatocytes 
(Zeisberg, Yang et al. 2007), cholangiocytes (Rygiel, Robertson et al. 2008), and bone 
marrow fibrocytes (Abe, Donnelly et al. 2001), sinusoidal hepatic stellate cells (HSC), which 
reside in the space of Disse (Figure 1.2), are the major source of MF in the liver (de Leeuw, 
McCarthy et al. 1984; Friedman 2008).  
 
1.2.1. Cellular interactions contributing to fibrosis and cirrhosis 
Many groups have focused their research on understanding the mechanisms that 
drive and maintain fibrogenic repair, which includes the interplay between a range of 
different liver cell populations.  In particular, paracrine signaling between liver MF and other 
cells in the injured liver microenvironment can initiate and sustain fibrosis.  Stressed and 
apoptotic hepatocytes can release signals such as CXC chemokines (Faouzi, Burckhardt et 
al. 2001; Canbay, Higuchi et al. 2002) or Hedgehog ligands (Rangwala, Guy et al. 2011) 
that can promote accumulation of liver MF.  Other liver epithelial cells, such as 
cholangiocytes, can also promote MF accumulation during liver injury via PDGF secretion 
(Grappone, Pinzani et al. 1999).  Reciprocally, liver MF can stimulate liver epithelial cells to 
release chemokine CXCL16 to recruit inflammatory NKT cells to perpetuate fibrosis 
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(Omenetti, Syn et al. 2009).  In addition to producing collagen, MF can further contribute to 
the fibrotic environment by initiating paracrine signaling with liver epithelial cells to promote 
Hedgehog signaling (Omenetti, Porrello et al. 2008).  MF also play an important role in 
angiogenesis (Ankoma-Sey, Matli et al. 1998; Ankoma-Sey, Wang et al. 2000), matrix 
remodeling through secretion of MMPs (Han, Yan et al. 2007), and the direct secretion of 
inflammatory signals such as TGF-β (Bachem, Meyer et al. 1992) or osteopontin (Syn, Choi 
et al. 2011) to help to sustain the inflammatory response associated with fibrosis. 
 
1.2.3. The role of liver progenitors in injury and repair 
Liver progenitors also play a major role in liver repair, although the source of these 
cells is still up for debate.  In multiple chronic liver diseases, observations of an expansion of 
cells in the bile ducts and Canals of Herring (Figure 1.2) suggested that this ductular 
reaction was directly linked to liver progenitor proliferation (Tan, Hytiroglou et al. 2002; 
Richardson, Jonsson et al. 2007).  Analysis of these cells in multiple species reveal they 
express multipotent stem cell markers (Cardinale, Wang et al. 2011), and Hedgehog 
(Omenetti, Yang et al. 2007), Notch (Fabris, Cadamuro et al. 2007), and Wnt (Apte, 
Thompson et al. 2008) signaling pathways have been implicated in their regulation.  Others 
have shown by lineage tracing that HSC could be the source of liver progenitors (Yang, 
Jung et al. 2008).  In this study, Yang et al. created a double transgenic mouse created by 
crossing a mouse with a HSC marker driving Cre and a LoxP reporter mouse.  After liver 
injury, sinusoidal cells, ductular cells, and hepatocytes all expressed the reporter tag, 
meaning that liver epithelial cells could be the progeny of HSC cells or derived from the 
same lineage.  The function of progenitors during liver injury is also disputed.  Different 
groups have indicated that progenitors can give rise to hepatocytes during injury (Yang, 
Wang et al. 2008) or that they contribute to fibrosis by differentiating into myofibroblasts 
(Loo and Wu 2008).  Paracrine signaling between activated HSC and progenitor cells can 
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also promote the expansion and accumulation of the progenitor population (Lin, Tang et al. 
2008). 
 
It is often thought that cancer is wound healing gone awry (Dvorak 1986).  In injured 
livers, molecular signals not present in healthy livers become activated.  As mentioned 
above, liver MF are heavily influential in the fibrogenic repair process via the paracrine 
signals they receive and secrete.  These same signals are also pertinent in cancer.  Given 
that HCCs emerge from this microenvironment, it is likely that cells and signals from the 
injured liver microenvironment contribute to progression of HCC. 
 
1.3. The tumor microenvironment  
A majority of research in the past 30 years has focused on the properties of tumor 
cells: sustaining proliferation, resisting apoptosis, evading growth suppressors, supporting 
angiogenesis, achieving replicative immortality, and eventual invasion and metastasis 
(Hanahan and Weinberg 2011).  Our understanding of cancer cells has grown exponentially 
as we continue to develop new models and tools, such as whole genome sequencing 
(Cancer Genome Atlas Research Network 2008; Cancer Genome Atlas Research Network 
2011; Cancer Genome Atlas Research Network 2012), to further appreciate how tumor cells 
acquire and maintain their neoplastic phenotypes.  As a result, novel systemic therapies 
have been developed in response to our knowledge of a cancer cell’s aberrant properties.  
Although some of these therapies are successful (e.g. imatinib), a majority are transient and 
moderately effective, while metastasis and recurrence looms in the future and dooms patient 
survival.  These clinical obstacles underscore the multiple collaborations tumor cells have 
with their microenvironment, by recruiting or using neighboring cells to further drug 
resistance and malignancy.   
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1.3.1. A historical understanding of the tumor microenvironment 
Early on, study of the tumor microenvironment focused on the ECM and endothelial 
cells.  Specifically, it was thought that both corrupted components of the ECM (Dvorak, 
Dvorak et al. 1979) or corrupt endothelial cells (Folkman 1971) promoted an environment 
suitable for angiogenesis.  In a study by Fukumura et al., orthotopic liver tumors or 
spontaneous breast tumors were transplanted or induced in mice expressing GFP under the 
control of the promoter for the angiogenic factor VEGF.  In both tumor models, VEGF-GFP 
positive cells accumulated in the mesenchymal compartment of the tumors, demonstrating 
that the VEGF production occurs in fibroblasts, not tumor cells (Fukumura, Xavier et al. 
1998).  Since these initial studies, our understanding of the tumor microenvironment has 
broadened. Over the past decade, there is an evolving sense that the many cells that 
constitute the microenvironment can influence tumors beyond angiogenesis. 
 
1.3.2. The role of the tumor microenvironment 
The tumor microenvironment consists of a heterogenous mix of different cells that 
interact with the tumor cell to promote malignant phenotypes.  One commonly studied 
example is the stromal production of mitogens that sustain the proliferative capacity of tumor 
cells: In a variety of tumors, virtually all studied stromal cell types, from immune cells to 
endothelial cells to fibroblasts, can secrete mitogenic and trophic factors such as EGF 
(Wang, Zhang et al. 2011), TGF-β (Rosenthal, McCrory et al. 2004), BMP2 (Mathieu, Sii-
Felice et al. 2008), HGF (Kuperwasser, Chavarria et al. 2004; Verras, Lee et al. 2007), and 
FGF (Yan, Fukabori et al. 1992).  Immune cells, endothelial cells, and fibroblasts also 
promote other malignant properties in tumor cells through similar juxtacrine signaling 
(Pietras and Ostman 2010). While some studies have revealed very direct relationships 
between stromal cells and cancer cells, other studies suggest a more intricate relationship.  
For instance, the secretion of both EGF by tumor associated macrophages and CSF-1 by 
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breast tumor cells is required for either cell to migrate, suggesting an almost commensal 
relationship between the two (Wyckoff, Wang et al. 2004).  In another example, elevated 
VEGF signaling from stromal cells in the tumor microenvironment (Fukumura, Xavier et al. 
1998) triggers angiogenesis and the creation of microvessels, which disrupt cellular tight 
junctions lining the vasculature, and leads to pericyte depletion and worse patient outcomes 
(Yonenaga, Mori et al. 2005).  As a result, a pericyte-depleted microenvironment leads to 
increased hypoxic and EMT signaling within breast cancer cells, which promotes metastatic 
behavior (Cooke, LeBleu et al. 2012).  Thus, interactions between cells in the tumor 
microenvironment are not restricted to one-dimensional signaling, but can be reciprocal and 
multi-layered. 
 
1.3.3. Tumors as wounds that fail to heal 
Since dysregulated wound healing is thought to advance malignancy, there has been 
renewed interest in the role of the cancer associated fibroblast (CAF).  It was posited that 
since fibroblasts and their cousins, myofibroblasts (MF) have major roles in wound healing 
(i.e. they are key cells involved in matrix remodeling), these cells would also have cancer 
nourishing properties.  One observation supporting this hypothesis is that following normal 
wound healing, the number of activated fibroblasts and MF decrease (Tomasek, Gabbiani et 
al. 2002) .  Yet in the tumor microenvironment, fibroblasts and MF maintain a constant 
presence, perhaps as a corollary of organ fibrosis (Kalluri and Zeisberg 2006). 
In more recent years, our understanding of interactions between fibroblasts and 
tumor cells has expanded and we now know that their contributions to tumorigenesis are 
multifaceted.  In addition to their impact on tumor cell proliferation, CAFs can directly 
stimulate tumor angiogenesis (Orimo, Gupta et al. 2005), chemoresistance (Wang, Li et al. 
2009), and metastasis (Jedeszko, Victor et al. 2009) through secretion of different factors 
and cytokines.  CAFs also promote malignant and metastatic phenotypes through 
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reorganization and remodeling of ECM (i.e. increased fibrotic injury).  In a prospective 
observational study of 439 patients with breast cancer, levels of fibrosis were found to be a 
potential prognostic parameter.  Patients with increased fibrosis had poorer survival, higher 
tumor recurrence, and higher distant organ metastasis (Hasebe, Sasaki et al. 2002).  
Additional studies in glioblastoma (Huijbers, Iravani et al. 2010), breast cancer (Levental, Yu 
et al. 2009), and HCC (Zhao, Cui et al. 2010) suggest that increased ECM stiffness and 
increased fibrosis accompanies cancer progression and can induce invasive properties of 
cancerous epithelia.  Moreover, the genetic or pharmacologic disruption of fibrosis 
prevented tumor progression in mouse models of breast cancer (Levental, Yu et al. 2009).  
Similarly, in a mouse model of pancreatic ductal adenocarcinoma, Olive et al. increased 
therapeutic delivery by ablating CAFs in the tumor microenvironment, which resulted in 
depleted desmoplasia surrounding the tumor and improved survival (Olive, Jacobetz et al. 
2009).  These studies support the idea that CAFs contribute to the tumor microenvironment 
through dysregulated wound healing and increased fibrosis, which supports a more 
aggressive tumor phenotype. 
 
1.3.4. The tumor microenvironment in HCC 
Recent studies in the liver have begun to unravel the relationship between liver MF, 
liver fibrosis, and HCC progression.  In 2008, a large study undertaken by Hosida et al. 
analyzed tissues from 307 patients with HCC.  Gene expression profiling was performed to 
identify a gene signature unique to patients with poor survival and time-to-recurrence.  While 
profiling of the tumors failed to generate a consensus gene signature able to predict survival 
time, profiling of liver tissue surrounding the tumor led to a reproducible signature predictive 
of prognosis, indicative that stromal tissue plays a role in HCC progression (Hoshida, 
Villanueva et al. 2008).  Furthermore, this poor-prognosis signature included genes 
commonly associated with liver MF, such as Fibrillin1, Col4a1, and Mmp7.  Mikula et al. 
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demonstrated that liver MF can augment hepatocellularcarcinogenesis: Simultaneous 
subcutaneous injection of malignant hepatocytes with liver MF in mice resulted in a more 
aggressive xenografts than malignant hepatocytes alone, due to induction of TGF-β and 
epithelial-to-mesenchymal transitions in tumor cells (Mikula, Proell et al. 2006).  Microarray 
analysis of hepatocytes in co-culture with liver MF revealed increased expression of genes 
associated with inflammatory cytokines and motility (Coulouarn, Corlu et al. 2012).  In the 
same co-culture, analysis of liver MF reaffirmed previous studies that demonstrated 
increased angiogenic potential (VEGFA) and matrix remodeling (MMP9).  While these 
studies demonstrate that crosstalk between malignant hepatocytes and liver MF are 
bidirectional and dynamic, much is still unknown about how liver MF drive 
hepatocellularcarcinogenesis and how malignant hepatocytes influence liver MF. 
 
The complexity of the numerous relationships between stromal cells and tumor cells 
underscores the difficulty of fully comprehending the role of the microenvironment in tumor 
progression.  To address this question, it is necessary to first understand how tumor cells 
and stromal cells can communicate.  Research has been directed towards secreted factors 
that can initiate and engage paracrine signaling, such as TGF-β or various growth factors 
and cytokines.  Other possibilities include morphogenic signaling pathways (e.g. Wnt, Notch, 
Hedgehog) and their ligands (β-catenin, Jagged, HH ligands), which play pivotal roles in 
fetal development, mediate crosstalk between epithelial and stromal compartments 
(Kolterud, Grosse et al. 2009), and become reactivated during adult injury and wound 
healing (Arwert, Hoste et al. 2012).  One candidate pathway that fits these criteria is 
Hedgehog signaling pathway, which is essential during development and becomes 
reactivated during organ injury and dysregulated in cancer. 
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1.4. Hedgehog signaling, an overview 
Our understanding of Hedgehog signaling came from humble and small beginnings.  
In 1980, Nüsslein-Volhard and Wieschaus set out to understand the genes regulating 
Drosophila development.  To accomplish this, they used a chemical screen to generate 
mutants with malformed bodies, and as a result, first identified Hedgehog as a critical gene 
for body polarity and segmentation (Nusslein-Volhard and Wieschaus 1980). The gene 
mutation corresponded to an abnormal dentricle formation that produced flies which looked 
like hedgehogs, thus granting it its apropos name.  In 1992, three labs independently cloned 
the Drosophila hh gene and showed that it encodes a secreted peptide, which paved the 
road for future discoveries of Hedgehog’s role in development and disease (Lee, von 
Kessler et al. 1992; Mohler and Vani 1992; Tabata, Eaton et al. 1992).   
Since then, we have found Hedgehog signaling to be a remarkably conserved 
pathway, critical in the development and patterning of many multicellular organisms (Ingham 
and McMahon 2001).  Hedgehog is also well known for its role in limb (Riddle, Johnson et 
al. 1993; Harfe, Scherz et al. 2004), neural tube (Roelink, Porter et al. 1995), and organ 
development (Motoyama, Liu et al. 1998).  The crucial role of Hedgehog signaling is 
validated by developmental defects that occur when Hedgehog signaling malfunctions.  
Mutations in the gene encoding SHH ligand in developing mammals can lead to 
holoencephalopathy (Belloni, Muenke et al. 1996).  A similar malformation occurs after 
exposure to the teratogen cyclopamine, which inhibits Hedgehog signaling activity (Binns, 
James et al. 1962). Thus, proper Hedgehog signaling is required for normal development.   
 
1.4.1. Hedgehog ligands 
Under certain conditions, HH-ligand producing cells generate and secrete HH ligands 
into the environment.  In mammals, three homologous Hh ligands have been identified, 
Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH).  These 
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ligands are first synthesized as propeptides, cleaved to generate an N-terminal fragment 
(Lee, Ekker et al. 1994), and undergo further lipid modifications (Porter, Young et al. 1996).  
The biological purpose for cells to secrete HH ligands into the environment still remain 
obscure but seem to depend on specific environmental stimuli.  For example, the liver and 
ventral pancreas both emerge from the ventral foregut endoderm, due to signaling from the 
cardiac mesoderm (Douarin 1975).  Deutsch et al. demonstrated that FGF signaling from 
cardiac mesoderm directs ventral foregut endoderm to express genes for liver development 
and stimulates SHH ligand expression in order to suppress pancreatic development genes 
(Deutsch, Jung et al. 2001).  The secretion of different mammalian HH ligands is also 
affected by location specific signals.  Pathi et al. found that SHH expression was required for 
digit duplication and lateralization, whereas IHH was not (Pathi, Pagan-Westphal et al. 
2001). However, in mice with constitutively active Hh signaling, IHH ligands, not SHH, are 
expressed by colonic epithelium (van Dop, Uhmann et al. 2009).  Overexpression of DHH 
and SHH ligands in basal cells of mouse skin results in a common phenotype different from 
IHH overexpression.  While IHH overexpression did not show any overt phenotype, 
epidermal progenitor cell hyperplasia, loss of epidermal tissue renewal, and spontaneous 
development of basal carcinoma lesions followed DHH and SHH overexpression, 
suggesting that these two ligands are responsible for regulating epidermal stem cell fate 
(Adolphe, Narang et al. 2004).  Signals from injured tissue can also drive HH ligand 
production: Both SHH and IHH ligands are expressed the environments of injured liver 
(Sicklick, Li et al. 2005), lung (Watkins, Berman et al. 2003), and kidney (Ding, Zhou et al. 
2012). 
 
1.4.2. Explaining Patched and Smoothened 
After secretion, HH ligands bind to the receptor Patched (PTC), a 12 trans-
membrane domain receptor on Hh-responsive cells.  All three ligands bind to PTC with 
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similar affinity and activate the Hh signaling cascade (Figure 1.3).  Binding of HH ligands to 
PTC relieves it of its normal function as an inhibitor of Smoothened (SMO) (Murone, 
Rosenthal et al. 1999), a 7 trans-membrane domain protein which facilitates Hh signal 
transduction (Corbit, Aanstad et al. 2005).  Although the mechanism by which PTC 
represses SMO is still unknown, it is thought that PTC inhibits SMO indirectly, possibly 
through the movement of a SMO-regulating small molecule across the cell membrane.  
Support for this hypothesis comes from the observation that PTC shares structural 
similarities to the resistance-nodulation-division (RND) family of bacterial proton-driven 
transmembrane transporters (Taipale, Cooper et al. 2002).  Mutations in the RND-
homologous regions of PTC decrease its ability to suppress Hh signaling activity.  
Furthermore, the Taipale et al. failed to note any specific and direct association between 
PTC and SMO in Hh-responsive cells, suggesting that a direct physical inhibition of SMO by 
PTC is unlikely.  One candidate for a small molecule regulator of SMO is oxysterols (Dwyer, 
Sever et al. 2007).  Oxysterols induce expression of Hh target genes through indirect 
activation of SMO.  In the model proposed by Dwyer et al., the authors suggest that by 
regulating SMO exposure to intracellular oxysterols, PTC is able to regulate SMO.  
Supporting these results is the observation that PTC shares significant homology with NPC1 
(which itself has homology with the bacterial RND family), a protein involved in LDL-derived 
cholesterol transport (Davies, Chen et al. 2000).  Other regulators of SMO include vitamin 
D3 (Bijlsma, Spek et al. 2006).  Despite multiple studies addressing this question, further 
research is needed to fully understand the mechanism behind PTC and SMO interactions. 
 
1.4.3. The glee club: GLI transcription factors 
Once activated, SMO localizes to the primary cilia and initiates an intracellular chain-
of-events leading to the activation of latent Zinc-finger transcription factors, the Glioma-
family of proteins (GLI1, GLI2, GLI3).  While GLI1 and GLI2 both function as transcriptional 
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activators, only GLI2 is required for proper Hh signaling transduction and embryonic 
development (Ding, Motoyama et al. 1998; Bai, Auerbach et al. 2002).  Regulation of GLI 
activity occurs through protein phosphorylation and nuclear localization (Figure 1.3).  All GLI 
proteins are negatively regulated through phosphorylation by PKA, GSK3b, or CK1 (Kaesler, 
Luscher et al. 2000; Riobo, Lu et al. 2006; Varjosalo, Bjorklund et al. 2008; Pan, Wang et al. 
2009). Activated SMO promotes Hh signaling by preventing the phosphorylation and 
ubiquitination of GLI proteins through a mechanism that seems to involve the AKT 
antagonism of PKA activity (Riobo, Lu et al. 2006). In mammals, there are conflicting studies 
on whether phosphorylation of GLI can also influence nuclear-cytoplasmic shuttling (Sheng, 
Chi et al. 2006).  Suppressor of Fused (SUFU), which binds to all three GLI proteins, is 
thought to act as a negative regulator of GLI nuclear localization (Stone, Murone et al. 
1999).  The exact mechanism by which SUFU regulates GLI proteins is not yet understood 
but several studies suggest that SUFU keeps GLI proteins in the cytosol  (Dunaeva, 
Michelson et al. 2003; Merchant, Vajdos et al. 2004), possibly via regulation of a leucine-rich 
nuclear export signal region on GLI (Kogerman, Grimm et al. 1999) or via recruitment of a 
histone deacetylase to competitively inhibit GLI binding sites in the nucleus (Cheng and 
Bishop 2002).  SMO counteracts these repressive activities by promoting the rapid 
ubiquitination of SUFU (Yue, Chen et al. 2009).  
 
1.4.4. Negative feedback control of Hedgehog signaling 
In the nucleus, GLI proteins bind to Hh-target genes, such as ptch1, gli1, gli2, gli3, 
opn, foxf1, foxm1, and hhip (Marigo, Johnson et al. 1996; Teglund and Toftgard 2010).  The 
transcription and translation of HHIP (Hedgehog interacting protein) provides an additional 
layer of negative feedback: HHIP competitively competes with HH ligands for binding to PTC 
and reduces pathway activity (Chuang and McMahon 1999). Another repressor/regulator of 
Hh signaling is GLI3 (Tole, Ragsdale et al. 2000) and loss-of-function mutants develop 
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similar phenotypes as mice with overexpressed Hh signaling.  The GLI3 repressor is formed 
after cleavage and degradation of the C-terminal domain following sequential 
phosphorylation by PKA, GSK3b, and CK1 (Tempe, Casas et al. 2006). SHH ligand 
downregulates the formation of the GLI3-repressor by inhibiting its phosphorylation (Wang, 
Fallon et al. 2000; Bai, Stephen et al. 2004). 
 
Although certain aspects of Hh signaling remain obscure, what is clear is that 
environmental context contributes to the activity of Hh signaling.  In development, active Hh 
signaling facilitates the crosstalk between epithelial and mesenchyme cell populations 
(Ingham and McMahon 2001).  Similar patterns of Hh signaling emerge after tissue injury.  
In the liver, following injury, Hh signaling is triggered, becomes reactivated, and plays an 
important role in repair.  Sustained and dysregulated Hh signaling in the liver leads to 
fibrosis, cirrhosis, and cancer. 
 
1.5. The role of Hedgehog signaling in liver disease 
After liver development, Hedgehog signaling becomes silenced.  In both in vitro (e.g. 
mouse embryonic stem cells vs. well differentiated hepatocytes) and in vivo (e.g. Ptc-lacZ 
mice) models, qRT-PCR and IHC analysis reveals that the Hh pathway is activated and 
present in early development but becomes silenced in mature cells (Sicklick, Li et al. 2006).  
In uninjured livers, there is little to no expression of HH ligands and evidence of Hh signaling 
activity (Sicklick, Li et al. 2006; Yang, Wang et al. 2008).  One possible explanation for 
suppressed Hh signaling in healthy livers is the high expression of HHIP, a Hh signaling 
repressor, by sinusoidal cells, observed in both in vitro (Yang, Wang et al. 2008) and in vivo 
(Choi, Omenetti et al. 2009) models. 
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1.5.1. Hedgehog signaling is required for liver repair and regeneration 
Hepatic injury triggers a wound healing response to regenerate the liver.  This 
response is regulated by autocrine and paracrine signals within and between hepatic cells 
and includes a reactivation of Hh signaling pathway.  Transient activation of Hh signaling is 
required after acute injury for livers to mount a proper wound healing response and once the 
injury signal is removed, the liver resolves the insult and Hh signaling is down-regulated 
(Omenetti, Popov et al. 2008).  For example, treating mice with a Hh inhibitor after partial 
hepatectomy (a model of acute liver injury) results in a lack of activated Hh signaling, 
impaired liver regeneration and epithelial cell proliferation, significantly reduces 
accumulation of liver MF and progenitors, and results in the death of mice after 72 hours 
(Ochoa, Syn et al. 2010).   
 
1.5.2. Clinical evidence for Hedgehog signaling in liver disease 
Sustained Hh activity, however, is widely observed in multiple chronic human liver 
diseases and is not limited to one single etiology.  Rather, sustained Hh signaling generally 
occurs in livers with faulty tissue regeneration.  The level of hepatic Hh signaling correlates 
with severity of liver disease: Both hepatocytic SHH ligand expression and stromal GLI2 
expression correlate with fibrosis stage (Guy, Suzuki et al. 2012).  Compared to healthy 
livers, patients with primary biliary cirrhosis, a chronic cholestatic liver disease, have livers 
that harbor many more cells expressing Hh signaling activity (i.e. PTC, GLI2, IHH 
expression) (Jung, McCall et al. 2007).  Additionally, the liver environments of patients with 
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (Syn, Jung et al. 2009), 
alcoholic liver disease (Jung, Brown et al. 2008), and viral hepatitis (Pereira Tde, Witek et al. 
2010) all harbor elevated HH ligand, PTC, and GLI2 expressing cells. Using liver sections 
from patients with alcoholic liver disease or viral hepatitis, Syn et al. and Pereira et al. further 
characterize the GLI2-positive, PTC-positive cells and demonstrate that these cells co-
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express alpha smooth muscle actin (ASMA) and Vimentin (VIM), both mesenchymal and 
myofibroblastic markers.  These observations suggest that the liver MF population is Hh-
responsive and Hh signaling promotes their hepatic accumulation.  Hh-responsive cells 
continued to be expressed in HCC, where they surround the tumor nodule (Pereira Tde, 
Witek et al. 2010).  Thus, strong clinical evidence suggests that continuous Hh signaling 
promotes liver fibrosis and worsen liver injury.  These clinical observations have been 
verified experimentally in mice with haploinsufficiency of ptc.  When these mice, which 
overexpress Hh signaling, are subjected to cholestatic liver injury (Omenetti, Porrello et al. 
2008) or hepatotoxic diets (Syn, Jung et al. 2009), liver MF accumulation is enhanced and 
fibrosis is worsened as compared to WT mice.   
 
1.5.3. Hepatocyte injury initiates Hedgehog signaling in the liver 
Since Hh signaling is quiescent in healthy, normal livers, the molecular initiators of 
Hh signaling must occur during liver injury.  Clinical observations that hepatocytes 
undergoing ER-stress related injury express high levels of SHH ligands implicated them as a 
potential culprit for initiators of hepatic Hh signaling (Rangwala, Guy et al. 2011).  In 
essence, stressed and apoptotic hepatocytes release SHH and IHH ligands via an Akt 
dependent mechanism.  This event initiates paracrine Hh signaling between wounded liver 
epithelia and surrounding stroma.  Two key experiments led to this current understanding of 
how Hh signaling is initiated in liver disease.  First, hepatocytes were isolated from 
transgenic Ikkβfl/fl mice.  In vitro disruption of the NFkβ pathway, by treating isolated 
hepatocytes with Cre recombinase, resulted in caspase-3 activation (i.e. indicating cell 
apoptosis) along with increased intracellular levels of SHH and IHH proteins (Jung, Witek et 
al. 2010). Second, isolated primary hepatocytes from WT mice were treated with 
tunicamycin to induce ER stress and found to release biologically active HH ligands possibly 
by an AKT related mechanism (Rangwala, Guy et al. 2011). 
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1.5.4. Hedgehog signaling activation affects multiple liver cell types 
While hepatocytes are not themselves Hh responsive, neighboring stromal cells are 
Hh responsive and include hepatic stellate cells (HSC), hepatic progenitors, immune cells, 
cholangiocytes, and endothelial cells.  These cells activate Hh signaling in response to HH 
ligands, which sets off a cascade of intracellular events to support the wound healing 
process.  HH ligands activate Hh signaling in HSC, which promotes pro-survival pathways.  
Reducing the bioavailability of HH ligands in culture significantly reduces proliferation and 
increases HSC apoptosis (Sicklick, Li et al. 2005).  In addition, HSC require active Hh 
signaling as they undergo EMT to transform into liver MF (Choi, Omenetti et al. 2009).  
Culture activated HSC upregulate Hh pathway genes (e.g. ptc, smo, and gli2) and 
downregulate Hh pathway inhibitors (e.g. hhip), whereas pharmacologic inhibition of Hh 
signaling with SMO antagonists reduces HSC differentiation into MF (Yang, Wang et al. 
2008; Choi, Omenetti et al. 2009).   
Liver progenitors are also Hh responsive and accumulate after liver injury (Sicklick, Li 
et al. 2006; Jung, Brown et al. 2008; Ochoa, Syn et al. 2010).  HH ligands enhance the 
growth, proliferation, and viability of liver progenitors (e.g. oval cells, immature ductular cells) 
that become mobilized to regenerate the liver after injury (Sicklick, Li et al. 2006; Omenetti, 
Yang et al. 2007), but these responses are blunted with Hh signaling inhibition (Ochoa, Syn 
et al. 2010).  Furthermore, in transgenic mice with unrestrained Hh signaling, the 
accumulation of injury-related Hh-responsive liver progenitors is enhanced. 
HH ligands fuel the inflammatory response by stimulating ductular epithelial cells to 
produce various chemokines that serve as chemoattractants for various liver immune cells, 
including NKT cells (Omenetti, Syn et al. 2009).  Activated Hh signaling in NKT cells results 
in enhanced proliferation, decreased apoptosis, and increased secretion of pro-fibrogenic 
cytokines, IL-13 and IL-4 (Syn, Witek et al. 2009).  Both NKT cells (Syn, Witek et al. 2009) 
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and activated cholangiocytes, (Witek, Yang et al. 2009) can also produce additional HH 
ligands, which further enhance Hh signaling in the injured liver microenvironment.  Given the 
broad impact of activated Hh signaling in cells that respond to liver injury, it is not surprising 
that Hh signaling inhibition potentially interferes with the activities of fibrosis-causing cells.  
Treating mice after partial hepatectomy with the Hh inhibitor cyclopamine results in a 
dramatic reduction in fibrosis (Ochoa, Syn et al. 2010), providing evidence that 
pharmacologic inhibition of Hh signaling can reverse fibrogenic repair. 
Taken as a whole, the result of chronic liver injury is a Hh-rich microenvironment that 
promotes continuous wound healing, caused in part by sustained Hh signaling.  
Dysregulated and sustained Hh signaling promotes a pro-fibrotic phenotype, which is an 
important risk factor for liver cancer.  Thus, it is reasonable to hypothesize that Hh signaling 
is also active in the liver tumor microenvironment.  In other solid tumors, increased Hh 
signaling leads to tumor progression, either in a ligand independent (i.e. malignant epithelia 
harbor Hh pathway mutations) or ligand dependent (i.e. dysregulated paracrine Hh signaling 
between the tumor cell and its environment) fashion. 
 
1.6. Over the hedge: Hedgehog signaling in cancer 
In 1996, the link between Hedgehog signaling and cancer was established in 
patients with basal cell nevus syndrome (BCNS, also known as Gorlin syndrome), an 
autosomal dominant disease predisposing patients to the development of basal cell 
carcinomas (BCC).  Linkage studies of patients with BCNS mapped the locus carrying the 
mutant gene to the chromosome 9q22 and later to the Ptc1 gene (Hahn, Wicking et al. 
1996; Johnson, Rothman et al. 1996).  Mice haploinsufficient for Patched-1 showed similar 
phenotypes as patients with BCNS but oddly, did not develop BCC (Hahn, Wojnowski et al. 
1998).  However, after exposure to ionizing radiation, these mice progressed to develop 
BCC (Aszterbaum, Epstein et al. 1999).  Targeted deletion of Ptc-1 in skin progenitors also 
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resulted in BCC lesions (Adolphe, Hetherington et al. 2006).  Together, these results 
suggested that 1) Ptc1 is a tumor suppressor, 2) a two-hit mechanism to Ptc-1 is required for 
cancer development, and 3) abnormal Hh signaling in the pre-neoplastic setting promotes 
malignancy. 
Since then, there has been mounting evidence that abnormal Hh signaling is 
involved in multiple cancers. In prostate cancer, high levels of Hh signaling have been 
observed (Karhadkar, Bova et al. 2004) and a positive correlation exists between the level of 
Hh signaling activity and the severity and aggressiveness of the disease (Sheng, Li et al. 
2004).  Elevated Hh signaling has been observed in glioblastomas (Verhaak, Hoadley et al. 
2010), pancreatic cancer (Thayer, di Magliano et al. 2003), renal cell carcinoma (Dormoy, 
Danilin et al. 2009), ovarian cancer (Bhattacharya, Kwon et al. 2008), esophageal cancer 
(Ma, Sheng et al. 2006), colon cancer (Varnat, Duquet et al. 2009), lung cancer (Watkins, 
Berman et al. 2003; Yuan, Goetz et al. 2007), melanoma (Stecca, Mas et al. 2007), and liver 
cancer (Sicklick, Li et al. 2006).  Knockdown of Hh signaling in various cancer cell lines 
appears to decrease cell malignancy. 
 
1.6.1. Ligand independent Hedgehog signaling in cancer 
Abnormal Hh signaling works in both ligand independent and ligand dependent 
modes to drive carcinogenesis.  Direct evidence for dysregulation of ligand independent 
Hedgehog signaling (i.e. endogenous mutations of core Hh signaling components) has been 
shown in BCC (Reifenberger, Wolter et al. 2005), medulloblastoma (Wolter, Reifenberger et 
al. 1997; Taylor, Liu et al. 2002), breast cancer (Nessling, Richter et al. 2005; Fiaschi, Rozell 
et al. 2009), pancreatic cancer (Thayer, di Magliano et al. 2003; Pasca di Magliano, Sekine 
et al. 2006), colon cancer (Xie, Johnson et al. 1997), and liver cancer (Sicklick, Li et al. 
2006). Aberrant Hh signaling has been shown to provide several advantages to the tumor 
cell, such as promoting cell proliferation and regulating cell cycle progression (Adolphe, 
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Hetherington et al. 2006).  GLI consensus binding sites have been found on cyclin D1 
(Yoon, Kita et al. 2002) and overexpression of GLI results in elevation of cell cycle regulator 
foxm1 (Teh, Wong et al. 2002).  Hh signaling also promotes cell survival, another cancer 
hallmark.  In BCC cell lines, binding sites for GLI were found on bcl2, a negative regulator 
molecule of apoptosis, and transfection of gli1 pcdna corresponded with dose dependent 
increases of bcl2 activity and decreased cellular apoptosis (Bigelow, Chari et al. 2004).  In 
gastric cancer cells, downregulating GLI activity by blocking SMO resulted in decreased bcl2 
expression (Han, Lee et al. 2009).  Thus, the association between GLI1 and blc2 appears to 
be conserved among multiple cancer types. 
Hh signaling is also an established effector of EMT, a process involved in tumor 
invasiveness and metastasis.  In ovarian cancer cell lines, overexpression of GLI1 increased 
cell mobility and invasiveness along with EMT genes such as vimentin and mmp1 (Liao, Siu 
et al. 2009).  Hh inhibition in pancreatic cancer cell lines resulted in downregulation of 
mesenchymal programming and invasiveness and upregulated epithelial genes such as E-
cadherin (Feldmann, Dhara et al. 2007).  Notably, overexpression of GLI1 in pancreatic 
cancer cells resulted in increased invasiveness (Feldmann, Dhara et al. 2007; Inaguma, 
Kasai et al. 2011). Similar observations are reported in breast cancer cells (Souzaki, Kubo 
et al. 2011), glioma cells (Wang, Pan et al. 2010), and gastric cancer cells (Yoo, Kang et al. 
2008).  Together, these studies help to explain the effectiveness of targeting GLI proteins to 
disrupt tumor xenograft growth of various cancers (Thayer, di Magliano et al. 2003; Lauth, 
Bergstrom et al. 2007).  
 
1.6.2. Ligand dependent, paracrine Hedgehog signaling in cancer 
While evidence for a ligand-independent mechanism for Hh signaling first advanced 
understanding of this pathway in cancer, a growing number of studies have challenged this 
assertion and provide data that tumorigenesis is driven by ligand-dependent paracrine Hh 
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signaling.  First, some animal models of oncogenic Hh signaling fail to drive tumor 
development.  For example, in two models of pancreatic ductal adenocarcinoma (PDAC) 
and prostate cancer, oncogenic SMO, despite being localized to malignant epithelial cells, 
was insufficient to drive the development of neoplastic lesions (Mao, Ligon et al. 2006; Tian, 
Callahan et al. 2009).  Secondly, these studies were followed by additional reports in both 
human breast (O'Toole, Machalek et al. 2011), pancreatic (Bailey, Mohr et al. 2009; Tian, 
Callahan et al. 2009) and prostate cancers (Fan, Pepicelli et al. 2004; Shaw, Gipp et al. 
2009) that while the HH ligand producing cell is the tumor epithelial cell, they themselves are 
not Hh-responsive.  Instead, these studies suggest that the Hh-responsive cells in tumors 
are the tumor associated stroma.  In fact, malignant HH-ligand producing pancreatic 
epithelia were found to be devoid of primary cilia, signifying that they lack a crucial 
component of autocrine Hh signaling (Bailey, Mohr et al. 2009; Seeley, Carriere et al. 2009).  
Yet orthotopic implantation of pancreatic cancer cells overexpressing SHH ligands resulted 
in tumors that were sensitive to Hh inhibition (Bailey, Mohr et al. 2009).  The authors 
showed that tumor stromal fibroblasts, not malignant epithelia, expressed primary cilia, SMO 
translocation into the cilia, and high Hh pathway activity.  Finally Yauch et al. used a large 
panel of over 100 colon, pancreatic, and prostate tumor epithelial cell lines to demonstrate 
that sensitivity to an antagonist of SMO did not correlate with Hh signaling activity (Yauch, 
Gould et al. 2008).  These landmark results suggested that previous studies demonstrating 
reduction in malignancy by SMO antagonists could have resulted from off-target drug effects 
rather than a true knockdown of Hh signaling.  Instead, these tumor epithelial cell lines were 
refractory to treatment while mesenchymal cell lines were two times more sensitive to the 
Hh inhibitor than the most sensitive cancer cell line.  However, these same malignant 
epithelial cell lines expressed large amounts of SHH and IHH ligands compared to normal 
epithelial cells.  Co-injection of HH-ligand producing tumor cells with fibroblasts harboring a 
genetic deletion of Smo produced reduced tumor burden in a mouse xenograft model, 
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suggesting that disruption of the paracrine Hh signaling between epithelial tumor cells and 
stromal cells can prevent carcinogenesis.   
 
1.6.3. Paracrine Hedgehog signaling promotes the hallmarks of cancer 
What are some potential advantages paracrine Hh signaling provide the tumor?  A 
number of papers have implied that that malignant epithelia use paracrine Hh signaling to 
recruit/activate Hh-responsive fibroblasts to promote fibrosis.  In an orthotopic model of 
pancreatic cancer, Bailey et al. used transformed pancreatic cancer cell lines 
overexpressing SHH ligands to demonstrate epithelial-secreted ligands contributed to the 
formation of desmoplasia and promotes the proliferation and differentiation of pancreatic 
fibroblasts (Bailey, Swanson et al. 2008).  Pancreatic cancers are notorious for being 
refractory to standard chemotherapies.  Olive et al. demonstrated that combinatorial 
treatment of a genetically engineered mouse model of PDAC with a SMO antagonist and the 
chemotherapeutic, Gemcitabine, resulted in decreased tumor burden (Olive, Jacobetz et al. 
2009).  These authors concluded that treatment with the Hh inhibitor both reduces 
desmoplasia and fibrosis surrounding the tumor nodule and increases the therapeutic drug 
delivery of Gemcitabine.  Finally, when compared to normal fibroblasts, BCNS patient-
derived fibroblasts heterozygous for Patched-1 expressed higher levels of pro-fibrotic 
molecules MMP1, MMP3, and tenacin C when cultured in vitro, adding more support that 
dysregulated Hedgehog signaling in tumor-associated fibroblasts contributes to increased 
fibrogenesis.  Aside from increasing fibrosis surrounding the tumor, paracrine Hh signaling 
also promotes tumor growth.  In two separate xenograft models, created from fibroblasts 
with increased Hh pathway activity combined with malignant epithelial cells overexpressing 
SHH ligands, grew significantly faster than their controls (Fan, Pepicelli et al. 2004; Shaw, 
Gipp et al. 2009). 
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1.6.4. Hedgehog signaling in HCC 
The question of how does Hh signaling contribute to liver cancer is still largely 
unknown.  Several studies would suggest that autocrine Hh signaling in liver tumor cells is 
elevated and is a major pathway responsible for tumor proliferation, viability, 
chemoresistance and invasion (Sicklick, Li et al. 2006; Cheng, Xu et al. 2009; Chen, Lingala 
et al. 2011; Chen, Lin et al. 2011; Lu, Zhao et al. 2012).  However most of these studies 
describing the advantages conferred by Hh signaling were performed in cell lines.  
Furthermore, evidence for overexpression of Hh signaling was found in whole liver tissue 
and does not account for cell-specific localization.  Addressing this, Pereira et al. performed 
immunostaining on human HCC samples and found that PTC(+) and GLI2(+) cells were 
localized to the stromal compartment surrounding the tumor nodule, suggesting a paracrine 
mechanism might exist for liver cancer to advance (Pereira Tde, Witek et al. 2010). 
 
1.6.5. Development of clinical inhibitors of Hedgehog signaling 
The prevalence of Hh pathway activity in a variety of cancers has led to drug 
development of Hh signaling inhibitors.  Interestingly, the development of Hh inhibitors 
began prior to its discovery in Drosophila or cancer.  Observations that sheep that ate the 
wild corn lily, Veratrum californicum, gave birth to one-eyed lambs, led to the isolation and 
synthesis of the compound cyclopamine.  Three decades later, it was found to inhibit Hh 
signaling (Cooper, Porter et al. 1998; Incardona, Gaffield et al. 1998).  Just like every major 
signaling pathway that has been found in pre-clinical models to drive cancer progression, 
the proof is in the pudding, or as it relates to patients, the effectiveness of inhibitors in 
clinical trials.  As of April 2012, there are seven Hh inhibitors under clinical development and 
all seven inhibitors antagonize SMO (Rudin 2012).  Six have already entered phase I/II 
clinical trials for various cancers, including BCC, brain cancers, CML, pancreatic cancers, 
bone cancers, head and neck cancers.  Vismodegib (GDC-0449) was the first targeted 
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inhibitor of Hh signaling to be approved for clinical treatment of BCC (Guha 2012).  
Vismodegib is considered a competitive inhibitor of SMO, and belongs to a class of 
cycopamine-derivatives that outcompete cyclopamine for binding to SMO.  However, to 
date, reproducible clinical responses to SMO inhibitors have only been reported in BCC 
(Sekulic, Migden et al. 2012) and medulloblastomas (Rudin, Hann et al. 2009).  In fact, a 
199 patient Phase II, randomized, double-blind, placebo-controlled study evaluating GDC-
0449 as first line therapy for previously untreated metastatic colorectal cancer yielded 
unsatisfactory results: Not only were there no statistically significant differences in outcomes 
between the two arms, but the hazard ratio for progression free survival actually favored the 
placebo group (Rudin 2012).  And despite significant responses in a Phase II trial in 
advanced BCC (overall disease control rate was over 86%), the median duration of 
response was 7.6 months and median progression free survival was 9.6 months.  Acquired 
resistance is attributed to mutations that alter SMO to prevent the binding of GDC-0449 to 
SMO (Yauch, Dijkgraaf et al. 2009).  Unique challenges remain to determine whether Hh 
signaling inhibition will provide therapeutic benefit to patients. 
 
Questions persist about therapeutic potential of Hh signaling inhibition in cancers 
because the method by which Hh signaling provokes cancer progression is still yet to be 
determined in multiple cancers.  Combination therapy might be a more favorable strategy if 
paracrine signaling between stromal and malignant epithelial cells is found to be a main 
driver of cancer progression.  But the broad evidence of both ligand-independent and ligand-
dependent mechanisms of Hh activity in many tumors, including liver cancer, suggests that 
Hh signaling is a potential and exciting novel target for pharmaceutical therapy.  And while 
the role of Hh signaling in pre-neoplastic livers is established, the lack of knowledge about 
the role of the Hh-responsive microenvironment in HCC underscores the necessity of 
additional research.  The results of preclinical Hh inhibition in liver cancer cell lines is 
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promising and with clinical inhibitors against Hh signaling being developed, understanding 
the mechanism of Hh signaling in HCC could open up new avenues for medical treatment. 
 
1.7. Metabolism in physiology and cancer 
Normal differentiated cells metabolize biochemical energy to synthesize adenosine 
triphosphate (ATP).  The energy released during metabolic respiration is stored as ATP.  
While both aerobic respiration and anaerobic respiration are processes that transform 
glucose into ATP, aerobic respiration is 15 times more efficient at generating ATP than 
anaerobic respiration.  Initially, both pathways begin with glycolysis, but during aerobic 
respiration, the two pyruvate generated at the end of glycolysis are further oxidized in the 
tricarboxylic acid (TCA) cycle and oxidative phosphorylation.  In glycolysis, glucose is 
transported into the cell via glucose transporters and trapped in the cytoplasm by glucose 
phosphorylation.  During glycolysis, a series of catabolic reactions converts one glucose 
molecule into two molecules of pyruvate, two NADH, and two net ATP (Figure 1.4).  In the 
presence of oxygen, pyruvate is further oxidized into acetyl-CoA by the pyruvate 
dehydrogenase complex and enters the TCA cycle.  This process oxidizes acetyl-CoA to 
carbon dioxide and generates additional units of the reduced coenzyme, NADH.  NADH is a 
highly reduced species that releases energy when oxidized.  To utilize this energy, a set of 
enzymes within the inner membrane of the mitochondria removes electrons from NADH and 
passes them to the terminal electron acceptor, oxygen.  This process is termed oxidative 
phosphorylation and establishes a proton gradient across the membrane of the mitochondria 
used by ATP synthase to drive the production of ATP, where the cell ultimately stores the 
energy released by respiration.  However, when oxygen is limited, anaerobic respiration 
occurs.  In anaerobic conditions, oxygen is not available as a final electron acceptor, and 
pyruvate, instead of entering the TCA cycle, is converted by lactate dehydrogenase into 
lactate (Figure 1.5).   In addition to generating ATP from glycolysis, this process is 
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necessary to recycle NADH back to NAD+, a required coenzyme for glycolysis.  When 
oxygen is resupplied, lactate is converted back into pyruvate to enter the aerobic respiration. 
 
1.7.1. Cancer metabolism 
Over 90 years ago, Otto Warburg first noted that the growth of cancer cells (from 
human skin, throat, intestine, penis and nose) relies upon enhanced anaerobic glycolysis, 
even when sufficient oxygen is available for oxidative phosphorylation (Warburg 1956).  
Warburg recognized that despite aerobic conditions, cancer cells (as opposed to normal 
cells) produce energy by high rates of glycolysis and lactic acid fermentation, yet have low 
rates of oxidative phosphorylation in the mitochondria (Figure 1.6).  Thus, cancer cells follow 
a pattern of glycolytic activity that mimics the activity of normal cells under hypoxic 
(anaerobic) conditions.  This observation was later termed the Warburg effect (Racker 
1972).  Warburg hypothesized that this was due to impaired respiration in the tumor cell 
(mitochondrial defects), although we now know this is not necessarily the case (Dang 2012).  
The FDG-PET scan is the direct clinical application of the Warburg Effect.  Briefly, a 
radiolabeled hexokinase substrate, 2-18F-2-deoxyglucose (FDG), is incorporated into the 
cell by glucose transporters and phosphorylated by hexokinase.  In oncology, this technique 
is used to label and monitor tumors and track metastatic growth on the assumption that 
glycolytic tumor cells have a high uptake of glucose (Ben-Haim and Ell 2009). 
 
1.7.2. Regulators of the Warburg Effect 
Warburg’s observation about tumor glycolysis renewed interest in the regulation of 
metabolism by the tumor cell.  Several associations between oncogenes and metabolic 
enzymes have been made (Fan, Dickman et al. 2010).  In this study, Fan et al. discovered 
that conditional activation of AKT leads to upregulation of glucose import and the Warburg 
effect.  Inhibiting PI3K signaling in a mouse model of lung adenocarcinoma leads to 
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decreased detection by FDG-PET, suggesting that disruption of PI3K/AKT signaling impacts 
tumor glucose transport (Engelman, Chen et al. 2008).  Other oncogenes, such as RAS and 
SRC also increase glucose uptake and the phosphorylation of glycolytic enzymes (Cooper, 
Esch et al. 1984; Flier, Mueckler et al. 1987).  A study by Matoba et al. showed that p53 is 
coupled to mitochondrial respiration.  Specifically, through Synthesis of Cytochrome c 
Oxidase 2 (SCO2), p53 regulates the cytochrome c oxidase complex, essential for oxidative 
phosphorylation.  In p53 deficient cells, the authors observed a shift towards cellular 
utilization of glycolytic pathways (Matoba, Kang et al. 2006). The metabolic reprogramming 
of tumor cells is also attributed to HIF1α, a transcription factor that is stabilized in response 
to hypoxia.  Multiple tumor cells have shown to have elevated HIF1α signaling (Sutter, 
Laughner et al. 2000) and HIF1α activation suppresses mitochondrial function through 
activating Pdk1 (Kim, Tchernyshyov et al. 2006; Papandreou, Cairns et al. 2006) and 
directly increases glycolytic-associated genes hexokinase II (Mathupala, Rempel et al. 
2001).  HIF1α binding sites have been found on the M2 isoform of pyruvate kinase (PKM2), 
which further promotes the idea that HIF1α regulates aspects of glycolytic metabolism in 
cells (Kim, Tchernyshyov et al. 2006).   
Pyruvate kinase, which catalyzes the conversion of phosphoenolpyruvate into 
pyruvate, has faced greater scrutiny as a key mediator of enhanced glycolysis in cancer 
cells (Christofk, Vander Heiden et al. 2008).  Christofk et al. discovered that tumor cells 
exclusively express PKM2, and switching cells from the M2 isoform to the M1 isoform of 
pyruvate kinase resulted in a “reversal” of the Warburg effect.  This phenotype included 
reduced lactate production, increased oxygen consumption, and a reduced ability to form 
tumors in nude mice xenografts.  Intriguingly, PKM2 was found to be necessary to stabilize 
HIF1α, suggesting that it participates in a positive feedback loop to promote HIF1a activation 
and also glucose metabolism in tumor cells (Luo, Hu et al. 2011).  Upregulation of PKM2 
can alter the malignant epithelial cell in many ways, including modifying histones and 
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regulating epigenetic changes (Yang, Xia et al. 2012), increasing tumor growth (Christofk, 
Vander Heiden et al. 2008), increasing bioavailability of nucleic acids (Ye, Mancuso et al. 
2012), and even further altering the metabolism of the cancer cell by promoting lipogenesis 
(Panasyuk, Espeillac et al. 2012). 
 
1.7.3. The tumor microenvironment and cancer metabolism 
Although the amount of information being uncovered about tumor metabolism is 
growing, questions still remain about how the tumor microenvironment influences the 
metabolic state of the cancer.  Two groups in ovarian and breast cancer have reported that 
the growth of tumor cells is enhanced by metabolic end-products of the surrounding stroma.  
In an co-culture model of stromal adipocytes and ovarian cancer cells, Nieman et al. 
demonstrated that adipocytes directly transfer lipids to ovarian cancer cells to promote in 
vitro and in vivo growth and migration (Nieman, Kenny et al. 2011).  Another group 
suggested that stromal fibroblasts in breast cancer are glycolytic themselves and secrete 
lactate into the microenvironment to promote growth and metastasis of breast cancer cells 
(Bonuccelli, Tsirigos et al. 2010).  The idea that metabolic, and specifically, glycolytic end 
products such as lactate, from stromal cells can support tumorigenesis is intriguing and 
demonstrates yet another method by which the microenvironment influences the growth of 
tumors.   
 
1.7.4. The impact of glycolytic end product lactate on tumor progression 
Elevated lactate levels in both plasma and within the tumor itself have also been 
associated with poor prognosis and overall survival in several types of cancer (Walenta, 
Wetterling et al. 2000).  Lacate itself has been shown to confer advantages to tumor cell 
viability and proliferation (Sonveaux, Vegran et al. 2008) and can enhance motility and 
migration of tumor cells (Goetze, Walenta et al. 2011).  Lactate also signals macrophages to 
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release mitogenic and angiogenic factors, indirectly contributing to tumor proliferation and 
angiogenesis (Jensen, Hunt et al. 1986). The impact of lactate on the tumor 
microenvironment is reinforced by additional evidence that tumor cells express higher levels 
of monocarboxylate transporter 1 (MCT1), a lactate importer, than non-malignant cells 
(Koukourakis, Giatromanolaki et al. 2007; Sonveaux, Vegran et al. 2008).  Inhibition of 
MCT1 causes antitumor effects, including reduced growth and increased necrosis of tumor 
xenografts, suggesting that targeting lactate associated transporters has therapeutic benefit.  
Another study which suggests that endothelial cells uptake lactate in the tumor 
microenvironment to promote angiogenesis would seemingly rule them out as a source of 
lactate production (Sonveaux, Copetti et al. 2012). 
 
1.7.5. Glycolytic regulation of liver MF 
In the pre-neoplastic environment of the liver, the metabolism of hepatic stellate cells 
is an important regulator of their fibrogenic potential.  In recently published work, our lab 
revealed a previously unsuspected “metabolism-centric” mechanism governing the fate of 
hepatic stellate cells (Chen, Choi et al. 2012).  We demonstrate that during culture (and in 
injured livers), the  trans-differentiation of quiescent HSC into myofibroblasts is mediated via 
a metabolic switch that favors glucose consumptive processes, and show that this global 
change in HSC metabolism is controlled by Hedgehog signaling.  Hh signaling orchestrates 
this myofibroblastic reprogramming of HSC by directing HIF1α-dependent induction of 
glycolytic enzymes, resulting in cellular accumulation of the glycolytic end-product, lactate.  
In HSC themselves, lactate accumulation was shown to orchestrate global phenotypic 
changes that cause those cells to become myofibroblastic, thereby enhancing their wound 
healing capabilities.  
 
These results suggest that in the pre-neoplastic liver, HSC glucose metabolism plays 
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an important role in development of fibrosis, and is mediated by Hh signaling.  It is possible 
that hypoxic environments upregulate glucose metabolism in fibrotic and pre-neoplastic 
livers, which later contribute their end-products to promote tumorigenesis.  Thus, the extent 
of metabolic contribution by liver cancer associated fibroblasts towards HCCarcinogenesis 
remains largely unknown and highlights the need for further study on the metabolism of liver 
cancer as a whole. 
 
1.8. Summary 
Hepatocellular carcinoma is a disease that afflicts many patients worldwide.  
Unfortunately for many patients with HCC, therapeutic options are extremely limited, 
creating a real patient-driven need for better therapies.  The largest risk factor for HCC is 
cirrhosis, and HCC commonly recurs in cirrhotic livers after tumor ablation.  The pre-
neoplastic cirrhotic microenvironment may promote the outgrowth of malignant hepatocytes, 
but the mechanisms involved remain obscure. Because deregulated, excessively fibrogenic 
repair of liver injury causes cirrhosis itself, one possibility is that stromal-epithelial 
interactions fuel HCC growth.  In multiple tumors, communication between stromal cells in 
the tumor microenvironment and tumor cells nurtures malignant phenotypes. An important 
signaling pathway that regulates crosstalk between stroma and epithelia is Hedgehog 
signaling, which plays critical roles in development, wound healing, and cancer.  This 
pathway is especially important in liver regeneration and is a potential candidate for 
therapeutic targeting in liver cancer.  Sustained Hedgehog signaling worsens liver fibrosis 
and regulates the behaviors of multiple cells involved in wound-healing.  Dysregulation of 
this pathway continues as liver cancer develops, which warrants investigation into a) 
whether active Hh signaling is required for tumor growth, b) does Hh signaling regulate 
communication between malignant hepatocytes and Hh-responsive liver MF, and if so, c) 
how these communications promote HCC.
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Figure 1.1.  Masson trichrome stained core liver biopsy of NAFLD with cirrhosis. 
Cirrhosis is characterized by the replacement of normal liver parenchyma with 
fibrous tissue composed of collagenous matrix.  Here fibrotic bands are stained blue by 
trichrome staining.  Histologically, cirrhosis contains nodular remnants of normal liver 
architecture (portal triads and central veins) that are separated by wide scars and thin 
fibrous septa.  Normal liver architecture is shown in the insert.  Note the lack of fibrogenic 
matrix in normal liver.
Collagenous matrix 
deposition 
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Figure 1.2.  Graphical representation of the liver architecture.  The liver receives blood 
from the portal vein and the hepatic artery, which run beside the common bile duct and form 
the portal triad.  The hepatic artery receives arterial blood and the portal vein receives blood 
from the gastrointestinal tract.  Blood is passed through the hepatic sinusoids and out of the 
liver through hepatic venules.  The central vein is a branch of the hepatic vein.  Hepatocytes 
are organized into cords that are separated by sinusoids.  Endothelial cells line the 
sinusoids and lie directly adjacent to hepatocytes.  The space between the endothelium and 
hepatocytes is the space of Disse.  Hepatic stellate cells occupy this perisinusoidal space.  
Kupffer cells are specialized macrophages in the liver and contribute to the inflammatory 
response during wound healing. 
(Figure is adapted from Wikipedia, n.d., Retrieved August 21, 2012, from 
https://en.wikipedia.org/wiki/File:Hepatic_structure2.svg.) 
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Figure 1.3.  Overview of the Hedgehog signaling pathway.   
36 
 
 
 
 
 
 
 
Figure 1.3.  Overview of the Hedgehog signaling pathway.  Hedgehog ligands interact 
with the Hh receptor, Patched (Ptc) which relieves Ptc-mediated repression of Smoothened 
(Smo), permitting Smo activation.  Activated Smo prevents the phosphorylation and 
ubiquitination of Glioma (Gli)-family proteins, leading to their accumulation and nuclear 
localization.  In the nucleus, Gli proteins bind to Hh-target genes and regulate the 
transcription of Hh-associated genes.  Factors like Hedgehog-interacting protein (HHIP) 
competitively inhibit Hh signaling by binding to HH ligands. 
(Figure is adapted from Hedgehog signaling in the liver. J Hepatol. 2011 Feb;54(2):366-73.) 
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Figure 1.4.  Overview of glycolysis.   
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Figure 1.4.  Overview of glycolysis.  Glycolysis begins when glucose is transported into 
the cell via glucose transporters.  Glucose is metabolized to pyruvate through a series of 
catalyzed reactions that occur during glycolysis.  In aerobic conditions, pyruvate 
dehydrogenase catalyzes the reaction that converts pyruvate to acetyl CoA which then 
enters the TCA cycle and is further oxidized in the mitochondria during oxidative 
phosphorylation.  The activity of pyruvate dehydrogenase is regulated by the enzyme 
pyruvate dehydrogenase kinase.  In anaerobic conditions, pyrvuate is coverted to lactate via 
the enzyme lactate dehydrogenase (LDH) during lactic acid fermentation.  Gray arrows 
indicate irreversible reactions.  
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Figure 1.5.  Anaerobic glycolysis.  In anaerobic conditions, glucose is converted to 
pyruvate but because of decreased oxygen availability, does not enter the TCA cycle.  
Instead, pyruvate is converted to lactate by lactate dehydrogenase (LDH) and as a result of 
this process, recycles NADH to NAD+.  The generation of 2 NAD+ molecules allows 
glycolysis to continue and thus the cell relies primarily on glycolysis for the production of 
ATP. 
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Figure 1.6. Overview of the Warburg Effect.  As discussed, cells metabolize glucose to 
pyruvate during glycolysis.  In the presence of oxygen, normal differentiated cells use 
oxidative phosphorylation to produce ATP.  However, cancerous or proliferative cells 
downregulate their use of oxidative phosphorylation in the mitochondria and instead produce 
ATP using primarily glycolysis.  As a result, lactate is often a side product of the Warburg 
effect. 
(Figure is adapted from Understanding the Warburg Effect: The Metabolic Requirements of 
Cell Proliferation. Science. 2009 May 22;324(5930):1029-33.) 
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CHAPTER II 
HEDGEHOG SIGNALING ANTAGONIST PROMOTES REGRESSION OF 
BOTH LIVER FIBROSIS AND HEPATOCELLULAR CARCINOMA IN A MURINE 
MODEL OF PRIMARY LIVER CANCER 
 
Summary  
Objective:  Chronic fibrosing liver injury is a major risk factor for hepatocarcinogenesis in 
humans. Mice with targeted deletion of Mdr2 (the murine ortholog of MDR3) develop 
chronic fibrosing liver injury. Hepatocellular carcinoma (HCC) emerges spontaneously in 
such mice by 50-60 weeks of age, providing a model of fibrosis-associated 
hepatocarcinogenesis.   We used Mdr2-/- mice to investigate the hypothesis that 
activation of the hedgehog (Hh) signaling pathway promotes development of both liver 
fibrosis and HCC. Methods: Hepatic injury and fibrosis, Hh pathway activation, and liver 
progenitor populations were compared in Mdr2-/- mice and age-matched wild type 
controls. A dose finding experiment with the Hh signaling antagonist GDC-0449 was 
performed to optimize Hh pathway inhibition. Mice were then treated with GDC-0449 or 
vehicle for 9 days, and effects on liver fibrosis and tumor burden were assessed by 
immunohistochemistry, qRT-PCR, Western blot, and magnetic resonance imaging. 
Results:  Unlike controls, Mdr2-/- mice consistently expressed Hh ligands and 
progressively accumulated Hh-responsive liver myofibroblasts and progenitors with age. 
Treatment of aged Mdr2-deficient mice with GDC-0449 significantly inhibited hepatic Hh 
activity, decreased liver myofibroblasts and progenitors, reduced liver fibrosis, promoted 
regression of intra-hepatic HCCs, and decreased the number of metastatic HCC without 
increasing mortality. Conclusions:  Hh pathway activation promotes liver fibrosis and 
hepatocarcinogenesis, and inhibiting Hh signaling safely reverses both processes even 
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when fibrosis and HCC are advanced.  
 
Introduction 
Hepatocellular carcinoma (HCC) is an insidious cancer that accounts for up to 1 
million deaths a year and is the third leading cause of cancer deaths worldwide (Rahbari, 
Mehrabi et al. 2011). Cirrhosis, a consequence of progressive liver injury and fibrosis, is 
the single largest risk factor for HCC (Luedde and Schwabe 2011). An altered wound 
healing response to chronic liver injury, with resultant dysregulated activation of 
myofibroblasts and progenitor cell populations, has been implicated in cirrhosis 
pathogenesis and eventual carcinogenesis (Schuppan and Afdhal 2008).  
Loss-of-function mutations in the hepatocyte canalicular phospholipid flippase 
MDR3 (ABCB4) have been associated with a wide range of human biliary diseases 
including progressive familial intrahepatic cholestasis type 3 (PFIC3), cholestasis of 
pregnancy, drug induced cholestasis and an adult biliary cirrhosis with features similar to 
primary sclerosing cholangitis (PSC) (Jacquemin 2001; Trauner, Fickert et al. 2007; 
Trauner, Fickert et al. 2008; Gonzales, Davit-Spraul et al. 2009). Mice with a targeted 
deletion of Mdr2 (the murine ortholog of MDR3) lack the liver-specific P-glycoprotein that 
transports phosphatidylcholine (PC) across the canalicular membrane. The absence of 
phospholipids in bile results in progressive sclerosing cholangitis with accompanying 
portal inflammation, ductular proliferation and portal fibrosis. Liver injury manifests 
shortly after birth and   hepatocellular carcinomas emerge spontaneously between 50 to 
60 weeks of age (Frijters, Ottenhoff et al. 1996; Van Nieuwkerk, Elferink et al. 1996; De 
Vree, Ottenhoff et al. 2000; Fickert, Zollner et al. 2002; Fickert, Fuchsbichler et al. 2004; 
Popov, Patsenker et al. 2005; Baghdasaryan, Fickert et al. 2008).  Unlike xenograft 
models that are widely utilized to examine mechanisms of- and treatments for- HCC, 
Mdr2-/- mice provide a model that parallels the natural evolution of HCC on a background 
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of chronic inflammation, liver injury and fibrosis (Katzenellenbogen, Mizrahi et al. 2007).  
Gene expression analyses in Mdr2-deficient mice and heterozygote controls 
have demonstrated  robust and sustained induction of multiple adaptive mechanisms 
that control cellular responses related to oxidative stress, inflammation, lipid metabolism, 
and proliferation, prompting speculation that these processes contribute to 
hepatocarcinogenesis (Katzenellenbogen, Pappo et al. 2006).  Although not formally 
assessed by earlier studies of Mdr2-deficient mice, another pathway that might play a 
role in fibrosis-associated hepatocarcinogenesis is Hedgehog (Hh), because Hh 
signaling has been implicated in both fibrogenic repair of liver injury and HCC. 
 The Hh pathway is an evolutionarily conserved signaling pathway that is 
activated when Hh ligands (Sonic hedgehog and Indian hedgehog) bind to Patched 
(Ptc), a transmembrane receptor that is expressed on the surface of Hh-responsive 
cells. Upon ligand binding, Ptc is inactivated, relieving its repression of Smoothened 
(Smo), a trans-membrane protein that mediates Hh signaling inside the cell.  Smo 
activation culminates in the nuclear localization of Gli-family transcription factors, Gli1, 
Gli2, and Gli3, which, in turn, regulate downstream gene expression. The pathway is 
quiescent in normal liver (Ramalho-Santos, Melton et al. 2000; Berman, Karhadkar et al. 
2003), but becomes reactivated as a repair mechanism in chronic liver injury (Omenetti, 
Yang et al. 2007; Omenetti and Diehl 2008; Omenetti, Popov et al. 2008; Omenetti, 
Porrello et al. 2008; Syn, Jung et al. 2009).  Hh ligands promote the growth and viability 
of myofibroblasts, the accumulation of which leads to abnormal liver repair, fibrosis and 
eventual cirrhosis (Sicklick, Li et al. 2005; Choi, Omenetti et al. 2009). Hh ligands also 
serve as viability and proliferative factors for liver epithelial progenitors, and expansion of 
this compartment has been linked to the formation and maintenance of hepatocellular 
carcinomas (Huang, He et al. 2006). The possibility that Hh pathway activation 
contributes to hepatocarcinogenesis is supported by the fact that Sonic hedgehog (Shh) 
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ligand expression is noted in approximately 60% of human HCCs, and expression of the 
Hh-regulated genes, Gli1 and Ptc, occurs in 50% of human tumors (Patil, Zhang et al. 
2006; Sicklick, Li et al. 2006; Pereira Tde, Witek et al. 2010; Chen, Tang et al. 2011).  
 Based on these observations, we postulated that Hh pathway activation 
contributes to the pathogenesis of both liver fibrosis and fibrosis-associated HCC.  To 
test this hypothesis, we treated aged Mdr2-deficient mice with the Hh pathway inhibitor, 
GDC-0449, a small-molecule inhibitor that binds to Smoothened (SMO). This agent was 
selected because of its human safety profile in phase 1 trials, as well as its effectiveness 
in solid organ tumors like basal cell carcinoma (BCC) and medulloblastoma (Rudin, 
Hann et al. 2009; Von Hoff, LoRusso et al. 2009; Lorusso, Rudin et al. 2011).  Our aims 
were to determine whether or not mice with advanced liver disease and HCCs would 
tolerate Hh pathway inhibition and experience improvements in liver fibrosis and/or 
tumor burden. 
 
Methods 
Mice.  Mdr2-/- mice were a gift from Dr. Detlef Schuppan (Beth Israel Deaconess Medical 
Center, Boston, MA).  Age matched FVB/NJ wild type mice were obtained from Jackson 
Laboratory (Bar Harbor, ME).  All mice were housed with a 12-h light-dark cycle and 
given water and standard chow ad libitum.  At ages, 2, 4, 12, 36 52 and 62-weeks, mice 
were sacrificed under general anesthesia.  Liver weight and body weight were recorded, 
serum and liver tissue were collected. Animal studies were approved by the Institutional 
Animal Care and Use Committee as governed by the National Institute of Health’s 
“Guide for the Care and Use of Laboratory Animals”, Duke University Animal Welfare 
Assurance Number A3195-01. 
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Serum AST/ALT determination.  Serum aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured using kits commercially available from Biotron 
Diagnostics (66-D and 68-D respectively; Hemet, CA) according to the manufacturers’ 
instructions. 
 
Western Blot.  Total protein was extracted from snap frozen whole liver tissue in RIPA 
buffer.  Samples were pooled by age (2-4 samples per age group) except as noted. 
Western blot analysis was performed as previously described.  Membranes were probed 
with the following primary antibodies: Sonic hedgehog (sc-9024; Santa Cruz 
Biotechnology, Santa Cruz, CA), Indian hedgehog (ab39634; Abcam), -actin (sc-47778, 
Santa Cruz Biotechnology), Gli2 (18-732-292462, Genway, San Diego, CA). All 
antibodies were diluted 1:1000 and were incubated at 4oC overnight.  Western blot 
images were acquired using a FluorChem HD2 digital darkroom system (Cell 
Biosciences, Santa Clara, California).    
 
Immunohistochemistry.  4μm formalin-fixed, paraffin-embedded samples were dewaxed 
and rehydrated.  To evaluate tissue architecture, slides were stained with hematoxylin 
and eosin (H&E) and Sirius red per standard protocol.  For immunohistochemistry, slides 
were incubated in 3% hydrogen peroxide/methanol. Antigen retrieval was performed by 
heating in 10mM sodium citrate buffer or 0.25% pepsin (K19; Invitrogen, Carlsbad, CA) 
for 10 minutes. Sections were blocked (Dako Envision, Carpinteria, CA) and incubated 
with primary antibodies overnight at 4oC: glioblastoma-2 (Gli-2; 18-732-292462; 1:2000; 
Genway, San Diego, CA); cytokeratin 19 (Troma-III; Hybridoma Bank, Iowa City, IA; 
1:500); α-fetoprotein (AFP) (Dako, 1:1000); Indian hedgehog (Abcam; 1:750, 
Cambridge, MA); Polymer-HRP anti-rabbit (K4003; Dako) or anti-mouse (K40011; Dako) 
or MACH3 mouse AP polymer kit (MP530, Biocare Medical, Concord, California, USA) 
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were used as secondary antibodies.  3,3'-Diaminobenzidine (DAB) Substrate 
Chromogen System (K3466; Dako) and/or Ferangi Blue (Biocare) was employed in the 
detection procedure. Omitting primary antibodies from the reactions eliminated staining 
which demonstrated staining specificity. Images were acquired on an Olympus IX71 
(Tokyo, Japan) inverted microscope using the DP2-BSW (Olympus) image acquisition 
software system. 
 
Quantitative Real-Time Reverse Transcription PCR. RNA was isolated from whole liver, 
as well as from resected tumor specimens had standard TriZol extraction as has been 
previously described (Choi, Omenetti et al. 2009). A table of primers has been included 
in the Supplementary Materials.  
 
Morphometry. Formalin-fixed liver and tumor sections were stained for CD44 and 
osteopontin as described above, and were quantified by morphometric analysis with 
MetaView software (Universal Imaging, Downington, PA). A minimum of 5 randomly 
selected 10x or 20x fields/section were evaluated for each mouse.  
 
Quantitative Immunohistochemical Analysis. Formalin-fixed liver and tumor sections 
were costained for Gli2 and CK19.  A minimum of 5 ductular regions, 20x fields per 
section, were evaluated for each mouse by counting the number of cells co-labelled. 
 
Hepatic hydroxyproline assay.  The hydroxyproline content in whole liver specimens was 
quantified colorimetrically as previously reported (Witek, Stone et al. 2009). 
 
GDC-0449 treatment.  In the initial, dose-finding cohort of animals, 16 Mdr2-/- mice (age 
57-68 weeks) were assigned to treatment with vehicle control (DMSO, n=5), 20mg/kg 
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GDC-0449 (n=5), or 40mg/kg GDC-0449 (n=6). Male-female ratios were balanced 
between the groups. GDC-0449 (Selleck Chemicals, Houston, TX) was freshly 
constituted daily in DMSO.  All mice were given a daily intraperitoneal injection for 9 
days.  On day 10, animals were sacrificed.  Samples were collected as above.  A second 
cohort of 20 Mdr2-/- mice (age 51-59 weeks of age) were subjected to whole body 
magnetic resonance imaging to assess tumor burden and then pairs of mice with 
comparable tumor burdens were assigned to treatment with either  DMSO (control, 
n=10) or 40mg/kg GDC-0449 (n=10).  Drugs were delivered as described above; MRI 
scanning was repeated after the 9th day of treatment; mice were sacrificed for necropsy 
and tissue harvest. 
 
Pathology.  H&E and sirius red staining of liver sections was evaluated by a board-
certified pathologist. Representative sections of tumor and non-tumor tissue were 
examined.  Tumor tissue was defined as grossly visible nodules that were at least 10mm 
in size and resectable.  
 
Abdominal magnetic resonance imaging.  Animals were assigned a blinding code, which 
was maintained during magnetic resonance (MR) data acquisition and analysis. MR 
mouse liver imaging was performed on a 7T Bruker Biospec 70/30 horizontal bore 
system (Billerica, MA). Animals were lightly anesthetized under isofluorane with 
continuous monitoring and maintenance of physiological parameters throughout the 
imaging session (~60 min for each animal). Axial and coronal 2D T2-weighted fast spin 
echo images (TURBO-RARE, TE/TR = 11 /4200 ms with 1 mm slice thick, matrix = 256 
X 256 and FOV of 2.4 cm X 2.4 cm, 5 averages, 0.0 mm interslice gap) images were first 
obtained for screening purposes and supplemental anatomic information. For directed 
tumor volumetric analysis, 64 contiguous 500 µM thick 3D FSE proton density images 
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biased towards T1 weighting (TURBO-RARE, TE/TR = 9 /1500 ms, matrix = 256 X 256 
X 64 and FOV 2.2 cm X 2.2 cm X 2.2 cm, 25 minutes duration) were acquired.  All 
imaging sequences were performed using respiratory gating.  
 Volumetric analysis from MR data sets was performed in Osirix software, an 
open source image processing application developed and maintained by Pixmeo 
(Geneva, SUI).  Liver tumors were manually segmented in each animal by a board-
certified radiologist (blinded to treatment) post-treatment. Selected areas were reviewed 
for consistency on coronal and sagittal representations, and cross-correlated with axial 
2D FSE images.  For volumetry, two separate volume measurements were obtained for 
each lesion, with the average volume then taken. Interrater reliability (kappa value) was 
= 0.97. T1 and T2-weighted scanning sequences were performed.  
 
Statistical analyses.  Results expressed as mean±SD. Significance established using the 
Student’s t-test. Differences were considered significant when p<0.05.  
 
Results 
Progressive accumulation of Hh-responsive cells in Mdr2-/- mice. 
Various forms of acute and chronic liver injury induce hepatic expression of Hh 
ligands and activation of Hh responsive cells.  Serum levels of AST and ALT were 
consistently higher in Mdr2-/- mice than age-matched controls (Figure 2.S1), confirming 
that the knockout mice had chronic liver injury. Thus, we surveyed livers from Mdr2-/- 
mice for Hh pathway activation. Compared to liver protein lysates from wild type 
controls, lysates from Mdr2-/- mice demonstrated an increase in Sonic hedgehog (Shh) 
and Indian hedgehog (Ihh) by Western blot analysis.  This was apparent at the first time 
point examined (2 weeks after birth) and maintained throughout the lifespan of the 
animals (up to 64 weeks of age) (Figure 2.1A).  Immunohistochemistry for the Hh-
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regulated transcription factor, Gli2, demonstrated progressive, age-related accumulation 
of cells with nuclear Gli2 staining in Mdr2-/- mice.  Such Gli2-positive cells included 
stromal cells, as well as hepatocytic and ductular cells (Figure 2.1B-C). Together, these 
data suggest that the Hh pathway is activated in chronically injured livers of Mdr2-
deficient mice, resulting in progressive expansion of various Hh-responsive cell 
populations. 
 
Treatment of Mdr2-/- mice with the Smoothened inhibitor, GDC-0449, is safe and 
decreases Hedgehog pathway signaling.   
To determine the appropriate dose of GDC-0449, a pilot study was done with 16 
aged (57-68 week old) Mdr2-/- mice. Animals were given a daily intraperitoneal injection 
of 20mg/kg GDC-0449 (n =5), 40mg/kg GDC-0449 (n=6), or DMSO vehicle control (n= 
5) for 9 days and then sacrificed. There was no statistical difference in mortality between 
the control and high dose (40 mg/kg) GDC-0449 groups.  At sacrifice, liver/body weight 
ratios of mice in the three groups were also similar, suggesting that a relatively short 
course of systemic treatment with GDC-0449 at 40mg/kg is well tolerated by mice with 
advanced liver disease and HCC (Figures 2.1.S2A-B).  Western blot analysis of liver 
lysates from this cohort of animals demonstrated that GDC-0449 treatment caused a 
decrease in Shh ligand levels at the higher dose, and Gli2 expression attenuation at both 
doses (Figure 2.S2C). 
 
Hedgehog signaling inhibition with GDC-0449 abrogates effects of Hh signaling on target 
gene expression.  
Based on the data acquired in our dose-finding study, a second cohort of Mdr2-/- 
mice (51-59 weeks of age) were assigned to treatment with vehicle (DMSO; n=10) or 
40mg/kg GDC-0449 (n=10) via daily i.p injection for 9 days.  Overall survival between 
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the two groups in the second cohort was equal, with no deaths in the DMSO treatment 
group and 1 death in the GDC-0449 treatment group secondary to iatrogenic injury. Both 
the liver parenchyma and tumors of treated mice showed decreased expression of the 
Hh pathway target Gli2 (Figures 2.2A-B). Real-time PCR analysis of resected tumors 
revealed that GDC-0449 treatment released the inhibitory effects of Hh signaling on 
PPARγ, causing a significant increase in its gene expression (Figure 2.2C). Treatment 
with GDC-0449 also caused a significant decrease in expression of Gli1, another Hh 
target gene (Figure 2.2D).  
 
Hedgehog signaling inhibition with GDC-0449 reduces liver fibrosis.  
Mdr2-/- mice demonstrated progressive age-related increases in hepatic 
expression of alpha-smooth muscle actin (α-sma), a marker of myofibroblastic hepatic 
stellate cells (Figure 2.3A, top panel).  This was accompanied by enhanced expression 
of pro-fibrogenic factors, such as transforming growth factor TGF-β and platelet derived 
growth factor PDGF-β (Figures 2.S3A-B), and progressive fibrosis, as evidenced by 
Sirius red staining (Figure 2.3A, bottom panel) and quantification of the hepatic 
hydroxyproline content (Figure 2.3B). Treatment with GDC-0449 decreased α-sma-
expressing myofibroblastic cells, hepatic expression of TGF-β and PDGF-β, Sirius red 
staining, and hydroxyproline content, demonstrating that Hh pathway inhibition reduced 
liver fibrosis (Figures 2.3C-D and Figures 2.S3C-D). 
 
Hedgehog signaling inhibition with GDC-0449 decreases accumulation of liver progenitor 
cells.  
In response to injury, progenitor populations in the liver proliferate.  Hence, 
immunohistochemical analysis for progenitor markers, such as cytokeratin-19 (CK-19) 
and α-fetoprotein (AFP), showed age-related increases in Mdr2-/- mice (Figure 2.4A). Co-
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staining for CK19 and Gli2 confirmed that the progenitor population was Hh responsive 
(Figure 2.4B). Upon treatment with GDC-0449, progenitor markers decreased (Figure 
2.4C), indicating that Hh signaling was required to maintain progenitor populations 
during tumorigenesis, and that Hh inhibition was sufficient to shrink the size of  
progenitor populations even in mice with advanced HCC.  
 
Decreasing Hedgehog signaling reduces expression of osteopontin and prevents 
accumulation of osteopontin-responsive (CD44-positive) cells. 
Stem/progenitor cell populations for many types of cancer, including HCC, are 
thought to be enriched with cells that express CD44, a receptor for the stem cell growth 
factor, osteopontin (Yang, Fan et al. 2008; Orian-Rousseau 2010). Osteopontin 
expression is regulated by Hh signaling (Syn, Choi et al. 2011).  Therefore, we examined 
the effects of GDC-0449 on osteopontin and its receptor, CD44. Immunohistochemistry 
and quantitative morphometry demonstrated that inhibition of the Hh pathway with GDC-
0449 significantly decreased osteopontin staining within primary liver tumors (Figure 
2.5A). Similar treatment-related decreases in CD44+ tumor cells were also noted (Figure 
2.5B). Gene expression analysis showed that expression of both osteopontin and CD44 
mRNAs also tended to decrease in GDC-0449-treated mice (Figure 2.5C). Together, 
these results suggest that Hh signaling may regulate putative liver cancer 
stem/progenitor cells by modulating availability of osteopontin. 
 
MRI and histological evidence of liver tumor involution following GDC-0449 treatment. 
To evaluate the potential impact of changes in matrix and progenitor cells on 
HCC, pre- and post-treatment tumor volumes were analyzed using magnetic resonance 
imaging (Figures 2.6A-B). An analysis of tumors in mice without overt metastasis 
demonstrated that tumor volumes decreased in mice that received a 9 day course of 
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GDC-0449-treatment, while vehicle-treated animals evidenced persistent tumor growth 
(Figure 2.6C; -6.7% +/- 11.7% vs 22.7% +/-9.1%, p = 0.03). This data correlated with 
necropsy findings: Only 56% of GDC-0449-treated mice had visible liver tumor nodules, 
compared to 80% of the DMSO mice (Table 2.1). Furthermore, both MRI and necropsies 
showed a decreased number of metastasis in GDC-0449-treated mice compared to 
vehicle-treated controls (Table 2.1). Histological analysis of H&E-stained liver sections 
was also performed on all animals from both cohorts. If tumor nodules were not grossly 
visible or greater than 10 mm in size, the samples were excluded from analysis. 
Microscopic tumor nodules in GDC-0449 treated animals demonstrated increased rates 
of hemorrhagic infarct (20% vs 0%; Figure 2.6D, top panel), microvesicular steatosis 
(40% vs 0%, Figure 2.6D, middle panel), acidophilic necrosis and degenerative 
cytoplasmic changes (70% vs 40%, Figure 2.6D, bottom panel) in comparison to tumors 
from vehicle treated animals. Thus, findings on MRI, necropsy, and liver histology were 
consistent and demonstrated that Hh pathway inhibition caused significant regression of 
primary and metastatic HCC. 
 
Discussion 
We studied Mdr2-/- mice to determine whether or not activation of the Hh pathway 
contributes to hepatocarcinogenesis during chronic fibrosing liver injury. Mdr2-deficient 
mice lack a phospholipid flippase that is required for normal bile formation, and 
consequently exhibit liver injury and ductular proliferation from a young age.  All afflicted 
mice eventually develop significant liver fibrosis and metastatic HCC. Our results 
demonstrate that this pathology is accompanied by progressive activation of the Hh 
pathway.  Introduction of a specific inhibitor of the key Hh signaling intermediate, 
Smoothened, reduced pathway activity and proved that sustained Hh signaling was 
required to maintain the expanded populations of liver myofibroblasts and progenitors 
69 
that had accumulated in the damaged livers.  Moreover, treating aged Mdr2-deficient 
mice ( which already had advanced liver fibrosis and HCC) with the Hh pathway inhibitor 
significantly reduced liver fibrosis and tumor burden, demonstrating for the first time that 
inhibiting Hh signaling has clinically-relevant, therapeutic value for both liver fibrosis and 
HCC.  Even more exciting is evidence that the prohibitive effect on hepatic tumor growth 
in vivo pertains to both intra-hepatic HCC and distant metastasis. 
In addition, our results provide insight into some of the underlying mechanisms 
involved. Hepatic production of Hh ligands was increased in mice that developed 
progressive liver fibrosis and invasive HCC. These mice also demonstrated consistently 
higher serum aminotransferase levels, in keeping with other evidence that Mdr2 
deficiency provokes chronic hepatocyte injury (Smit, Schinkel et al. 1993; Mauad, van 
Nieuwkerk et al. 1994).  Various stressors that reduce hepatocyte viability have been 
shown to induce production and release of Hh ligands by wounded hepatocytes (Jung, 
Witek et al. 2010; Rangwala, Guy et al. 2011).  Thus, hepatocyte injury is likely one of 
the factors that increases Hh ligand generation in mdr2-deficient livers. Myofibroblastic 
cells and ductular-type progenitors that progressively accumulate in chronically injured 
livers also produce Hh ligands, as well as other factors, such as PDGF-β, that stimulate 
autocrine-paracrine synthesis of Hh ligands (Omenetti, Popov et al. 2008; Yang, Wang 
et al. 2008). Relative to age/gender matched healthy control mice, aged mdr2-deficient 
mice with ductular reactions and liver fibrosis demonstrated higher hepatic mRNA levels 
of PDGF-β, suggesting a mechanism by which the fibrogenic repair response itself might 
perpetuate excessive hepatic accumulation of Hh ligands. The latter concept is 
supported by evidence that inhibiting Hh signaling with GDC-0449 reduced accumulation 
of myofibroblasts and ductular-type progenitors, decreased expression of PDGF-β, and 
suppressed hepatic expression Hh ligands in mice that remained at risk for hepatocyte 
injury due to genetic deficiency of Mdr2. 
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Chronic over-production of Hh ligands has important pathobiological implications 
because mice that generated increased Hh ligands also demonstrated excessive 
activation of the Hh pathway in their livers.  This was evidenced by larger numbers of 
cells with nuclear staining for the Hh-regulated transcription factor, Gli2, and enhanced 
expression of various Hh-target genes, including Gli1 and osteopontin. In such animals, 
we showed that treatment with a highly specific antagonist of Smoothened was able to 
suppress all of these responses, consistent with published evidence that activation of 
Smoothened in Hh-responsive cells promotes nuclear localization of Gli2, and 
consequent induction of Gli1 and osteopontin transcription (Das, Harris et al. 2009; 
Omenetti, Choi et al. 2011).  Osteopontin, in turn, has been shown to promote 
myofibroblast accumulation and liver fibrosis in mice (Machado and Cortez-Pinto 2011; 
Syn, Choi et al. 2011).  It also acts via its receptor, CD44, to enhance the viability and 
growth of certain types of liver progenitors, including liver cancer stem/progenitor cells 
(Haramaki, Yano et al. 1995; Yang, Fan et al. 2008; Orian-Rousseau 2010; Rangwala, 
Omenetti et al. 2011). Hence, the Hh pathway might be modulating both liver fibrosis 
and HCC outgrowth by regulating the autocrine/paracrine availability of osteopontin. 
Myofibroblasts and ductular progenitor cells are also important sources of other 
pro-fibrogenic factors (e.g., PDGF-β and TGF-β) that are capable of activating Gli2 via 
mechanisms that do not require Smoothened (Dennler, Andre et al. 2007; Friedman 
2008; Dennler, Andre et al. 2009). We observed increased hepatic expression of both 
PDGF- -β in Mdr2-deficient mice.  This suggests that Smoothened-
independent mechanisms that re-enforce the effects of the canonical Hh pathway may 
evolve during fibrogenic repair. In mdr2-deficient mice, however, GDC-0449 significantly 
reduced expression of TGF-β an
demonstrating that canonical Hh signaling with resultant Smoothened activation is 
ultimately required to fully engage noncanonical pathways that rely on interaction of 
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TGF-β and PDGF-β with their respective receptors to activate Gli2 in injured, fibrotic 
livers.  
Finally, the fact that liver fibrosis/cirrhosis is a major risk factor for the 
development of HCC should not be misconstrued to imply that fibrosis per se causes 
cancer.  It is conceivable that fibrosis and HCC each result from some adaptive 
response that occurs during chronic liver injury. Our results demonstrate that injury-
related activation of the Hh pathway typifies an adaptive response that is both pro-
fibrogenic and pro-carcinogenic.  This discovery, in turn, provides novel evidence that 
helps to explain why fibrosis and HCC often develop in the same livers.  As such, it has 
immediate clinical relevance to the many cirrhotic patients with HCC.  Additional 
research will be required, however to delineate the precise down-stream mechanism(s) 
involved and to determine which (if any) of those subsequent fibrogenic and 
carcinogenic processes are inter-dependent, and which are totally independent of each 
other.   
Proof that inhibition of Hh signaling substantially reduced the hepatic content of 
myofibroblasts and progenitors suggests that these cell types promote and/or maintain 
the outgrowth of malignant hepatocytes. This finding, in turn, provides a starting point for 
further research.  Indeed, others have reported that Smoothened antagonists lead to the 
involution of pancreatic cancers by influencing tumor angiogenesis (Olive, Jacobetz et 
al. 2009).  Myofibroblasts are known to be an important source of vascular growth 
factors, such as VEGF (Ankoma-Sey, Wang et al. 2000; Lee, Semela et al. 2007; Witek, 
Yang et al. 2009), and we found increased hepatic expression of VEGF and its receptor, 
VEGFR1, in the diseased livers of Mdr2-deficient mice compared to the healthy livers of 
age/gender-matched controls (data not shown). Hence, it is possible that myofibroblast 
depletion exerted a negative impact on the hepatic vasculature that ultimately resulted in 
HCC involution.  This concept is supported by evidence that GDC-0449 tended to 
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suppress hepatic expression of VEGF/VEGFR1 (data not shown) and increased 
necrosis in the HCC of GDC-0449-treated mice. Hh signaling is also known to maintain 
various progenitor populations (Katoh and Katoh 2009; Tanaka, Nakamura et al. 2009; 
Song, Yue et al. 2011).  Previously, we reported that Hh ligands function as autocrine 
and paracrine survival signals for liver progenitors and showed that liver myofibroblasts 
are an important paracrine source of Hh ligands that serve this purpose (Sicklick, Li et al. 
2006; Jung, McCall et al. 2007; Jung, Brown et al. 2008; Yang, Wang et al. 2008; Jung, 
Witek et al. 2010). Liver progenitors, in turn, generate Hh ligands that provide paracrine 
signals that re-enforce the growth of liver myofibroblasts (Fleig, Choi et al. 2007; 
Omenetti, Syn et al. 2009).  Given this background, it is not surprising that blocking Hh 
signaling with a Smoothened antagonist resulted in the mutual depletion of both cell 
types.  To our knowledge, however, by demonstrating marked treatment-related 
decreases in CD44, cytokeratin-19, and α-fetoprotein within HCC tumors, the current 
data provide the first evidence that Smoothened antagonists reduce populations of cells 
that exhibit features of tumor stem/progenitor cells.  Further investigation is required to 
ascertain how aberrant Hedgehog signaling promotes these cancer stem cell 
compartments.  
 In conclusion, our findings in the Mdr2-/- mouse model of progressive liver fibrosis 
and spontaneous hepatocarcinogenesis demonstrate that increased production of Hh 
ligands and progressive accumulation of Hh-responsive cell types, such as 
myofibroblasts and liver progenitor cells, precede the emergence of HCC, and persist 
after the development of HCC.  Despite advanced liver fibrosis and HCC, a short course 
of treatment with a highly-specific and clinically available Hh signaling inhibitor is well-
tolerated and demonstrates appreciable anti-tumor effects. Thus, Hh pathway inhibition 
with GDC-0449 merits evaluation as a potential treatment for HCC arising in cirrhotic 
patients, providing a novel treatment option for an emerging disease with a poor 
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prognosis and limited therapeutics.
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Figure 2.1. Increased  hepatic Hedgehog (Hh) pathway activity in Mdr2-/- mice. 
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Figure 2.1. Increased  hepatic Hedgehog (Hh) pathway activity in Mdr2-/- mice.  
A. Western blot analysis for Sonic Hedgehog (SHh) and Indian Hedgehog (IHh) 
in whole liver extracts pooled from young Mdr2-/- mice (2-16 weeks old), old (36-64 
weeks old) Mdr2-/- mice and age-matched controls (n=3-5 mice/group/time point). A 
representative Western blot demonstrating results from young mice is shown.  
Mean±SEM data from older mice are graphed. B. Representative liver sections stained 
to demonstrate Gli2 from young (4 wk old), middle aged (36 wk old) and old (52 wk old) 
Mdr2-/- mice.  Little Gli2 expression was noted in wildtype mice at any age, so results 
from a representative 36 wk old wild type mouse is shown. (10x) C. Quantitative Gli2 
immunohistochemical data.  The number of nuclear Gli2(+) cells was counted in at least 
5 high power fields (HPF) per liver section in Mdr2-/- mice and wild type controls at 4, 36 
and 64 weeks of age (n=3-4 mice/group/time point) and mean±SEM are graphed. 
*p<0.05, **p<0.01 in Mdr2-/- groups vs. respective controls 
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Figure 2.2. Hedgehog (Hh) inhibitor, GDC-0449, abrogates effects of Hh signaling 
within liver parenchyma and HCC nodules. 
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Figure 2.2. Hedgehog (Hh) inhibitor, GDC-0449, abrogates effects of Hh signaling 
within liver parenchyma and HCC nodules. A. Liver sections stained for Gli2 from 
representative DMSO- and GDC-0449- treated mice (40x). Quantitative Gli2 
immunohistochemistry data in non-tumor livers of mice treated with DMSO or GDC-0449 
(n=9-10/group) are graphed as mean±SEM (**p<0.01. The number of ductular cells with 
Gli2 positive staining were counted in each portal tract/section under 40x magnification.  
B. Tumor sections from the same mice were also stained to demonstrate Gli2. Results 
from representative DMSO- and GDC-0449-treated mice are displayed. Quantitative Gli2 
immunohistochemistry data were generated by counting nuclear Gli2 positive ductular 
and hepatocytic cells in tumor sections under 40x magnification.  Results are graphed as 
mean±SEM Gli2-positive cells/40x high power field (**p<0.01)   C-D Quantitative reverse 
transcription-PCR (qRT-PCR) analysis of whole liver RNA from DMSO-(open bar) and 
GDC-0449 (black bar) treated mice.  C. PPAR-γ, a gene that is normally repressed by 
Hh signaling.  D. Gli1, a gene that is induced by Hh signaling. Mean±SEM are graphed 
(**p<0.01). 
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Figure 2.3. GDC-0449 treatment reduces fibrosis in Mdr2-/- mice. 
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Figure 2.3. GDC-0449 treatment reduces fibrosis in Mdr2-/- mice. 
A. Immunohistochemical staining for α-SMA (top panel) and Sirius red   (bottom 
panel) in sections of non-tumor liver from representative age-matched Mdr2-/- and 
wildtype mice (10x). B. Pooled Hepatic hydroxyproline content of 2-52 wk-old wildtype 
(WT) and age-matched Mdr2-/- mice (n=3-5/group). Results in Mdr2-/- mice were 
normalized to that of age-matched WT mice and graphed as  fold change.  Data are 
displayed as mean +/- SD (*p<0.05)  C. Non-tumor liver sections stained for α-SMA (top 
panel, 20x) and Sirius red (bottom panel, 10x) in representative DMSO- and GDC- 
treated Mdr2-/- mice. D. Heptic hydroxyproline content of DMSO- and GDC- treated mice 
(n=9/group). Results in GDC-0449-treated mice were normalized to that of DMSO 
vehicle-treated mice and graphed as fold change.  Data are displayed as Mean +/- SEM 
(*p<0.05). 
80 
 
Figure 2.4. Effects of Mdr2 deficiency and Hedgehog (Hh) inhibition on hepatic 
progenitor populations. 
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Figure 2.4. Effects of Mdr2 deficiency and Hedgehog (Hh) inhibition on hepatic 
progenitor populations. 
 A.  Immunohistochemical staining of liver sections from representative, age-
matched Mdr2-/- and wildtype mice for progenitor markers, cytokeratin-19 (CK-19) (top 
panels) and α -fetoprotein (AFP) (bottom panels) (20x).  B. Representative micrograph 
of a portal triad in liver of an Mdr2-/- mouse, demonstrating co-localization of CK-19 
(blue) and Gli2 (brown)  in the ductular compartment (40x). C. Quantitative Gli2 and 
CK19 immunohistochemistry in DMSO- and GDC-0449-treated Mdr2-/- mice (n=9-
10/group). The number of  Gli2 and CK19 double-positive ductular-appearing cells were 
counted  within tumors under 20x magnification.  Mean±SEM double(+) cells t per high 
power field (HPF) are graphed (* p <0.05) D. QRT-PCR analysis of AFP in tumor RNA 
from mice treated with DMSO (open bar) or GDC-0449 (closed bar) Results in the GDC-
0449-treated mice were normalized to that of the mice treated with DMSO vehicle and 
graphed as Mean±SEM (*p<0.05). 
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Figure 2.5.  Inhibition of Hh signaling decreases osteopontin and osteopontin-
responsive (CD44) positive cells in tumors and peri-tumoral tissues of aged Mdr2-/- 
mice. 
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Figure 2.5.  Inhibition of Hh signaling decreases osteopontin and osteopontin-
responsive (CD44) positive cells in tumors and peri-tumoral tissues of aged Mdr2-/- 
mice. 
A. Tumor sections from representative DMSO-  and GDC-0449 treated Mdr2-/- 
mice were stained to demonstrate osteopontin (OPN) Representative sections are 
displayed (Right panel). OPN staining was quantified by morphometric analysis of at 
least 5 HPF per tumor section using 20x magnification (n=5 mice/group).Results in the 
GDC-0449-treated group were normalized to that of the group treated with DMSO 
vehicle and graphed as fold change.  Data are displayed as Mean±SEM (**p<0.01).  B.  
Immunohistochemical staining for the osteopontin receptor, CD44, in peri-tumoral 
tissues of representative DMSO- and GDC-0449- treated Mdr2-/- mice. (Right panel) 
CD44 staining was quantified by morphometric analysis as described in A.  Results in 
GDC-0449-treated mice were normalized to those of vehicle-treated controls and 
graphed as Mean±SEM (**p<0.01).  C. QRT-PCR analysis of liver tumor RNA from 
DMSO- (open bar) and GDC-0449- (closed bar) treated Mdr2-/- mice for OPN (left) and 
CD44 (right). After normalization to results in the DMSO-treated group, Mean±SEM were 
graphed (*p<0.05). 
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Figure 2.6.  Hh pathway inhibition decreases in liver tumor volume by magnetic 
resonance imaging (MRI) and induces histologic features of tumor involution. 
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Figure 2.6.  Hh pathway inhibition decreases in liver tumor volume by magnetic 
resonance imaging (MRI) and induces histologic features of tumor involution. A. 
Representative cross-sectional image of intrahepatic tumor as identified by contrast-
enhanced MRI following GDC-0449 treatment. B.  Representative MRI images of 
sagittal, coronal, and oblique perspectives used for volumetric analysis. C. Change in 
tumor volume were quantified by computerize generated volumetric measurements and 
graphed as Mean±SD (*p<0.05). D. Micrographs of representative histologic changes 
induced by, GDC-0449, treatment. Top panel shows tumor necrosis; middle panel 
demonstrates fatty degeneration; bottom panel show vacuolated tumor cells with 
pyknotic nuclei. 
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Table 2.1.  Effect of GDC-0449 treatment on intrahepatic HCC and HCC 
metastases. 
  
 
Surgical Resection MRI Imaging 
Vehicle Treatment Vehicle Treatment 
Intrahepatic Tumor 
Nodules 
80% 56% 78% 50% 
Metastases 20% 0% 50% 20% 
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Figure 2.S1. Evidence of ongoing liver injury in Mdr2-/- mice. AST and ALT 
measurements from Mdr2-/- mice and their age-matched wild type counterparts at 
various time points. Each data point represents n=2-7 animals and Mean±SD is 
graphed. (*p< 0.05 vs the age-matched wild-type control). 
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Figure 2.S2. Systemic treatment of GDC-0449 treatment is well tolerated in Mdr2-/- 
mice with advanced liver disease and HCC. A. Daily body weight measurements were 
obtained for all animals in each of the three treatment groups and graphed over time. 
Data expressed as Mean±SD. B. Liver to body weight ratios of animals in each of the 
three treatment groups.  Data expressed as Mean±SD. C. Western blot analysis for Shh, 
Gli1, Gli2 and actin (loading control) in whole liver extracts from Mdr2-/- mice treated 
with vehicle, 20mg/kg GDC-0449, and 40mg/kg GDC-0449. Liver extracts from each 
treated mouse were loaded individually. 
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Figure 2.S3. Increased hepatic expression of TGFand PDGF in Mdr2-/- mice is 
reversed by GDC-0449 treatment.  Whole liver RNA was isolated from Mdr2-/- mice and 
age/gender-matched wild type controls (WT) (n=3 mice/group)and QRT PCR was done 
to compare expression of  (A) TGF and (B) PDGF.  Similar approaches were used to 
assess the effects of a 9 day course of treatment with either the Hh pathway inhibitor 
GDC-0449  or vehicle (DMSO) on expression of  (C) TGF and (D) PDGF in Mdr2 -/- 
mice (n=5 mice/group).  Gene expression was normalized to expression of S9 in the 
same samples; mean +/- SEM values were calculated; values in the experimental 
groups were graphed relative those in the respective controls. P values are shown. 
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 CHAPTER III 
PARACRINE HEDGEHOG SIGNALING DRIVES METABOLIC CHANGES 
IN HEPATOCELLULAR CARCINOMA 
 
Summary 
Hepatocellular carcinoma (HCC) typically develop in cirrhosis, a condition 
characterized by Hedgehog (Hh) pathway activation and accumulation of Hh-responsive 
myofibroblasts (MF).  Although Hh signaling generally regulates stromal-epithelial 
interactions that support epithelial viability, the role of Hh-dependent MF in 
hepatocarcinogenesis is unknown.  Here we used human HCC samples, a mouse HCC 
model, and hepatoma cell/MF co-cultures to examine the hypothesis that Hh signaling 
modulates MF metabolism to generate fuels for neighboring malignant hepatocytes.  The 
results identify a novel paracrine mechanism whereby malignant hepatocytes produce 
HH-ligands to stimulate glycolysis in neighboring MF, resulting in release of MF-derived 
lactate that the malignant hepatocytes use as an energy source.  This discovery reveals 
new diagnostic and therapeutic targets that might be exploited to improve the outcomes 
of cirrhotic patients with HCC.   
 
Introduction 
Hepatocellular carcinoma (HCC) is one of the most common deadly forms of 
cancer worldwide (Forner, Llovet et al. 2012).  HCCs typically develop in cirrhotic livers 
(Forner, Llovet et al. 2012).  The latter compromises recovery from extensive liver 
resection, and restricts chemotherapy options and efficacy.  Therefore, survival depends 
mainly upon detection of tumors that are small enough to be safely ablated.  Better 
screening and preventative strategies are needed, however, because the number of 
HCCs that are already advanced at diagnosis is increasing, and the population at risk for 
96 
HCC is growing due to the rising incidence of cirrhosis (Forner, Llovet et al. 2012).  
Improved understanding of the early events in hepatocarcinogenesis would help to 
optimize prevention, early diagnosis, and treatment of HCC. 
Evidence that HCC occur in 1-5% of cirrhotic patients annually suggests that the 
cirrhotic microenvironment promotes the outgrowth of malignant hepatocytes (Ye, 
Takayama et al. 2010). However, the mechanisms involved remain obscure.  One 
possibility is that that stromal-epithelial interactions fuel HCC growth because 
deregulated, and excessively fibrogenic, repair of liver injury causes cirrhosis itself (Jou 
and Diehl 2010).  The major producers of fibrous matrix during liver injury are 
myofibroblasts (MF), and cirrhotic livers harbor large numbers of these cells.  The role of 
MF in HCC pathogenesis/progression is unclear, however, despite evidence that MF-
derived factors mediate key aspects of the wound healing response including matrix 
turnover, recruitment of inflammatory cells, vascular remodeling, and outgrowth of liver 
epithelial progenitors (Friedman 2008).  The pivotal importance of MF in cirrhosis 
pathogenesis justifies evaluating their role in hepatocarcinogenesis.   
A key regulator of MF is Hedgehog (Hh), a developmental morphogenic signaling 
pathway (Omenetti, Choi et al. 2011). Hh pathway activity is barely detectable in healthy 
livers but becomes robust during all types of liver injury.  Injured liver epithelial cells are 
important drivers of this process because injury stimulates the wounded epithelia to 
produce and release Sonic hedgehog (Shh) and Indian Hedgehog (Ihh) ligands, as well 
as other soluble factors, that promote Hh signaling in neighboring Hh-responsive stromal 
cells (Jung, Witek et al. 2010; Rangwala, Guy et al. 2011).  Like other Hh-responsive 
stromal cells, MF express the Hh ligand transmembrane receptor, Patched (Ptc) (Choi, 
Omenetti et al. 2009).  Interaction of epithelia-derived HH-ligands with Ptc results in the 
activation of Smoothened, the Hh signaling-competent co-receptor.  This leads to 
accumulation and nuclear localization of Glioma-family proteins (Gli1, Gli2, Gli3) which 
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regulate the transcription of Hh-responsive genes that control proliferation, viability, and 
differentiation of the stromal cells.   Exchange of paracrine signals between Hh-
producing epithelia and Hh-responsive stroma orchestrates organogenesis during 
development. Similar mechanisms are presumed to modulate some types of 
carcinogenesis based on findings in mouse models of pancreatic and prostate cancer 
(Gipp, Gu et al. 2007; Olive, Jacobetz et al. 2009).  Although increased Hh signaling has 
been documented in human HCC (Sicklick, Li et al. 2006), and liver MF are known to be 
a Hh-responsive cell type, the possibility that HCC growth might be regulated by 
paracrine Hh signaling between MF and malignant hepatocytes has not, to our 
knowledge, been examined.  
 Recently, we demonstrated that treating a mouse model of fibrosis-associated 
HCC with a Hh signaling inhibitor caused advanced HCCs to regress (Philips, Chan et 
al. 2011).  Tumor involution was accompanied by MF loss and fibrosis improvement.  
This suggests that the anti-cancer actions of the Smoothened antagonist may have 
resulted from deletion of Hh-responsive MF, and justifies further work to identify how MF 
might support the growth of malignant hepatocytes.  Here we evaluate the hypothesis 
that Hh signaling modulates MF metabolism to generate fuels for neighboring malignant 
hepatocytes.  Given that HCCs, like many other epithelial cancers, exhibit enhanced 
glycolysis (i.e., the Warburg effect) (Kitamura, Hatano et al. 2011), we asked if HCC 
glycolytic activity was influenced by Hh signaling in tumor-associated MF. 
 
Materials and Methods 
Human subjects. The Duke Department of Pathology computer database was searched 
for cases of HCC arising in nonalcoholic fatty liver disease (NAFLD) patients from 2007 
through 2011. Five cases were identified from resections, hepatectomies, and explants. 
Random tissue blocks containing both tumor and adjacent non-tumor were used. 
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Mice. Mdr2-/- mice were a gift from D. Schuppan (Beth Israel Deaconess Medical Center, 
Boston, MA).  10 Mdr2-/- mice (age 51-59 weeks of age) were assigned to treatment with 
either Vehicle (DMSO, n=5) or 40mg/kg GDC-0449 (n=5) and treated for 9 days as 
previously described (Philips, Chan et al. 2011).   
 
Immunohistochemistry.  Liver specimens fixed in formalin and embedded in paraffin 
were cut into 4μm sections, dewaxed, hydrated, subsequently incubated in 3% hydrogen 
peroxide/methanol for 15 min to block endogenous peroxidase. To evaluate tissue 
architecture, slides were stained with hematoxylin and eosin (H&E) per standard 
protocol.  Antigen retrieval was performed by heating in 10mM sodium citrate buffer or 
0.25% pepsin (K19; Invitrogen, Carlsbad, CA) for 10 minutes. Sections were blocked 
(Dako Envision, Carpinteria, CA) and incubated with primary antibodies overnight at 4oC: 
Sonic Hedgehog (Epitomics 1843-1; 1:6000), Pyruvate kinase M2 (Cell Signaling; 
1:1000), Glioblastoma-2 (Genway 18-732-292462; 1:2000);  α smooth muscle actin 
(Dako; 1:800) (Dako, 1:1000); Mct4 (Santa Cruz; 1:1000), Indian hedgehog (Abcam; 
1:750); Polymer-HRP anti-rabbit (K4003; Dako) or anti-mouse (K40011; Dako) were 
used as secondary antibodies.  3,3'-Diaminobenzidine (DAB) Substrate Chromogen 
System (K3466; Dako) and/or Vino Green (Biocare) was employed in the detection 
procedure. Omitting primary antibodies from the reactions eliminated staining which 
demonstrated staining specificity. Images were acquired on an Olympus IX71 (Tokyo, 
Japan) inverted microscope using the DP2-BSW (Olympus) image acquisition software 
system. 
 
Quantitative Immunohistochemical Analysis. Formalin-fixed human and mouse tumor 
sections were stained for GLI2 and costained for GLI2 and PKM2.  A minimum of 10 
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randomly selected 200x field were evaluated for each mouse by counting the number of 
cells positive for GLI2 only and co-labeled for both GLI2 and PKM2. 
 
Quantitative Real-Time Reverse Transcription PCR. RNA isolated from cells, whole liver, 
as well as from resected tumor specimens had standard TriZol extraction as previously 
described (Choi, Omenetti et al. 2009). 15 ng of cDNAs was used to perform QPCR 
assay in duplicate with SYBR Green Supermix. Primer sequences listed in Supplemental 
Table 1. Expression of the examined genes was normalized against internal control 
gene (rodent β-actin or human β-actin) based on the threshold cycle (Ct) and relative 
fold change calculated by the 2-∆∆Ct method (Choi, Omenetti et al. 2009).  
 
Morphometry. Formalin-fixed human tumor sections (n=5) were stained for SHH, PKM2 
and mouse tumor sections (n=5) as described in the previous section; staining was 
quantified by morphometric analysis with MetaView software (Universal Imaging, 
Downington, PA). A minimum of 10 randomly selected 200x fields/section were 
evaluated for each human and mouse section. Each stain quantified by morphometric 
analysis was normalized to the non-tumor liver group (n=5 patients/group) or Vehicle-
treated group (n=5 mice/group).  
 
Cell culture. Clonally derived rat myofibroblastic line (8B cells) were obtained from M. 
Rojkind (George Washington University, Washington D.C., USA) (Greenwel, Schwartz et 
al. 1991) were cultured alone (monoculture), in a Transwell co-culture system with 
HepG2 cells (ATCC, Manassas, VA, USA), Huh 7.5 cells (C. Rice, Rockefeller 
University), or Panc 10.05 cells (Duke Cell Culture Facility).  MF monocultures were also 
treated with PBS-control or 1000 ng/ml recombinant Shh ligand (StemCell Technologies, 
Vancouver, Canada) +/- DMSO-vehicle or 3μM GDC-0449 (Selleck Chemicals, Houston, 
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TX), or conditioned medium from the other cells +/- IgG-control (R&D) or 10ug/ml 5E1 
Hh neutralizing antibody (Developmental Studies Hybridoma Bank, Iowa City, IA) for 24 
hours.  To characterize the effects of myofibroblast-tumor cell interactions in vitro, we 
used a Transwell co-culture system in which liver MF and hepatoma lines were cultured 
for 24 hours alone or in the co-culture system. To assess the effects of lactate on HepG2 
cells, cells were treated with control media and media containing 40μM of lactate (Sigma 
Aldrich) for 24 hours. Conversely, HepG2 cells were treated for 24 hours simultaneously 
with 40μM of lactate and either DMSO-vehicle or 10μM of FX11, a LDH inhibitor and gift 
from C. Dang (Johns Hopkins University, Baltimore, MD), to assess the effects of 
blocking lactate utilization. All cell lines were plated in triplicate for each experiment and 
grown as previously described (Choi, Omenetti et al. 2009; Rangwala, Guy et al. 2011). 
After normalization to respective controls, data from individual cultures were averaged to 
generate the result of each experiment.  All experiments were repeated three times; 
replicate results were used to calculate final mean +/- SEM values. 
 
Measurement of cellular lipid droplets. PFA fixed slide samples were stained with Oil 
Red O for 30 min at RT, followed by PBS washing. Oil Red O staining was quantified by 
morphometric analysis of at least 10 HPF per experiment using 200x magnification. 
 
Measurement of lactate and pyruvate. Cell culture media or whole cell lysate was 
prepared with Lactate Assay Buffer (Biovision, Mountain View, CA). 250μL of media or 
lysate was filtered through 10 kd column (BioVision, Mountain View, CA) and stored at -
80 0C for lactate and pyruvate measurement and, when calculating intracellular amounts, 
for a BCA assay (BioRad, Hercules, CA) to determine protein concentration for 
normalization. Lactate was measured with the Lactate Assay Kit (BioVision) and 
pyruvate was measured using the Pyruvate Assay Kit (BioVision) according to the 
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manufacturer’s manual and normalized to the protein concentration. 
 
Measurement of ATP. Whole cell lysates were prepared with ATP Assay Mix (Sigma 
Aldrich, St. Louis, MO) and ATP was immediately measured using the ATP 
Bioluminescent Assay Kit (Sigma Aldrich) according to the manufacturer’s manual. 
Results were normalized to protein concentration measured by a BCA assay (BioRad, 
Hercules, CA). 
 
Luciferase Reporter Assay. The Hh-responsive luciferase reporter assay was performed 
using Shh-LightII cells (ATCC, Manassas, VA, USA). Cells were treated with conditioned 
medium from HepG2 cells for two days. Briefly, Shh-LightII cells were stably co-
transfected with a Gli-responsive firefly luciferase reporter and a pRL-TK constitutive 
Renilla luciferase reporter. Firefly and Renilla luciferase activities were determined via a 
dual luciferase kit (Promega, Madison, WI, USA). In a parallel experiments, Shh-lightII 
cells were co-cultured with HepG2 cells in a Transwell system.  One day after plating, 
cells were harvested and Firefly and Renilla luminescence were measured. 
  
 
Results and Discussion 
Malignant epithelia produce HH-ligands and stroma is enriched with Hh-responsive, 
glycolytic MF in human HCC 
To investigate Hh ligand expression and localization in HCC, we performed 
immunohistochemistry for Sonic Hedgehog (SHH) ligand in archived paraffin-embedded 
tissues from 5 patients with HCC and cirrhosis caused by nonalcoholic fatty liver disease 
(NAFLD).  All of the HCCs demonstrated increased expression of SHH relative to their 
capsules and adjacent non-tumorous liver tissue (Figure 3.1A).  Within tumor nodules, 
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malignant hepatocytes were a major source of SHH ligand.  In contrast, nuclear staining 
for the Hh-regulated transcription factor, GLI2, was confined to the tumor-associated 
stroma.  Compared to adjacent nontumor liver, HCCs were also significantly enriched 
with GLI2(+) stromal cells (Figure 3.1B).  These findings suggest that malignant 
hepatocytes produce HH-ligands that promote Hh signaling in adjacent stromal cells.   
 To assess glycolytic activity in these HCC we stained sections for pyruvate 
kinase M2 (PKM2), a rate limiting glycolytic enzyme and well-validated marker of 
glycolysis (Christofk, Vander Heiden et al. 2008).  Unexpectedly, we found that PKM2 
staining localized to HCC stroma, rather than to the malignant hepatocytes themselves 
(Figure 3.1C).  Dual staining for GLI2 and PKM2 confirmed that the Hh-responsive 
stromal cells were glycolytic and showed that HCC stroma harbored greater numbers of 
glycolytic cells than adjacent nontumorous liver (Figure 3.1B, C). To further characterize 
these glycolytic stromal cells, we co-stained other sections for PKM2 and alpha smooth 
muscle actin (ASMA), a MF marker (Friedman 2008).  Expression of PKM2 co-localized 
with ASMA, demonstrating that the glycolytic tumor-associated stromal cells were Hh-
responsive MF (Figure 3.1D). 
 
Hh inhibitor depletes glycolytic MF from tumor stroma in murine HCC model 
Progressive liver injury and fibrosis occur in Mdr2-/- mice due to deficient 
transport of phosphatidyl choline into bile.  Primary hepatocellular carcinomas emerge 
spontaneously between 50-60 weeks of age, modeling the natural evolution of HCC 
during fibrogenic repair of various types of chronic liver injury (Katzenellenbogen, Pappo 
et al. 2006).    Therefore, we used immunohistochemistry to characterize the tumor-
associated stroma in HCC that were micro-dissected from these mice.  As noted in our 
human HCC cohort (Figure 3.1B-D), tumor-associated stroma in the mouse model was 
enriched with cells that co-expressed ASMA and PKM2 (Figure 3.2A).  Therefore, 
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glycolytic MF localize within the HCC-associated stroma in both species, and this seems 
to occur irrespective of the etiology of the underlying liver disease.  In human HCC, the 
glycolytic MF co-stained for GLI2 (Figure 3.1B) and thus, were presumed to be Hh-
responsive.  To examine the role of Hh signaling in regulating glycolytic activity in the 
murine tumor stromal cells, we compared expression of Glut1, a glucose transporter, 
and several key glycolytic enzymes in mRNA isolated from HCCs of Mdr2-deficient mice 
that had been treated with either vehicle or the Smoothened antagonist, GDC0449, for 9 
days prior to sacrifice.  Treatment with the Hh inhibitor reduced expression of mRNAs 
encoding Gli2, Glut1, glycolytic enzymes, and αSma (Figure 3.2B).  
Immunohistochemistry confirmed that reduced expression of MF- and glycolysis-
associated mRNAs was paralleled by depletion of tumor stromal cells that expressed 
ASMA, PKM2, and monocarboxylate transporter 4 (MCT4), a facilitator of lactate export 
(Halestrap and Price 1999) (Figure 3.2C).  
 
Paracrine Hh signaling between hepatoma cells and MF stimulates glycolysis in MF 
To determine if hepatoma cells generate soluble HH-ligands that might stimulate 
glycolytic activity in Hedgehog-responsive MF, we compared Gli-luciferase reporter 
activity in Shh–LightII cells that were exposed to conditioned medium from HepG2 cells, 
co-cultured with HepG2 cells in a Transwell system , or treated with control medium 
without or with recombinant SHH (Figure 3.3A).  Like recombinant SHH, exposure to 
HepG2 cell-derived soluble factors significantly increased Hh signaling in the Shh-LightII 
cells.  The stimulatory effect of HepG2 conditioned medium was abrogated by adding 
5E1, a Hh neutralizing antibody that blocks HH ligand-Ptc interaction (Berman, 
Karhadkar et al. 2003)  (Figure 3.3A).  Moreover, when HepG2 cells were replaced with 
cells that do not generate HH-ligands (Panc 10.05 cells) (Yauch, Gould et al. 2008) and 
experiments were repeated, no change in Shh-LightII cell luciferase activity was 
104 
observed (Figure 3.S1A).   The aggregate data, therefore, indicate that HepG2 cells 
generate soluble, biologically-active HH-ligands. 
 To determine if these HepG2-derived HH ligands functioned as inducers of MF 
glycolysis, we cultured a well-characterized rat liver MF line (8B cells) (Greenwel, 
Schwartz et al. 1991)  alone (monoculture) or in the Transwell system with HepG2 cells, 
and assessed MF glycolytic activity.  Co-culturing MF with HepG2 cells induced MF 
expression of mRNAs that encode key glycolytic enzymes (Figure 3.3B), and increased 
their lactate/pyruvate ratio, a measure of glycolytic activity (Figure 3.3C).  Treating MF 
with HepG2 cell-conditioned media had similar effects (Figure 3.3D).  The stimulatory 
effects of HepG2-conditioned medium on MF glycolysis were attenuated by adding 5E1 
to block HH ligand-Ptc interactions (Figure 3.3E), suggesting that HH-ligands are the 
factors that malignant hepatocytes release to induce glycolytic activity in neighboring 
MF.  To verify that activating Hh signaling in MF promotes glycolysis, we treated 
monocultures of liver MF with recombinant SHH (rSHH) ligand.  Compared to vehicle-
treated MF, MF treated with rSHH ligand had increased expression of genes encoding 
glycolytic enzymes (Figure 3.3F) and higher lactate/pyruvate ratios (Figure 3.3G).   
GDC-0449, a direct antagonist of the Hh signaling intermediate, Smoothened, reversed 
the effects of rSHH-ligand, confirming that MF glycolysis is Hh-dependent (Figure 3.3G).  
Treating MF with rSHH also significantly increased their secretion of lactate into the 
media, while  adding GDC-0449 reduced media lactate below basal levels, 
demonstrating that Hh signaling also regulates MF secretion of  lactate (Figure 3.3H).  
 
Lactate generated by glycolytic MF fuels lipogenesis in HepG2 cells   
Our aforementioned findings identified a novel Hh-dependent mechanism 
whereby malignant hepatocytes modulate the metabolic activity of tumor-associated MF.  
Because tumor stroma is generally believed to support the growth of malignant epithelial 
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cells, we used the Transwell co-culture system to evaluate the related hypothesis that 
MF-derived glycolytic end-products (such as lactate) enhance net energy homeostasis of 
malignant hepatocytes.  Compared to mono-cultured HepG2 cells, HepG2 cells that 
were co-cultured with liver MF demonstrated significant accumulation of Oil Red O-
stained lipid droplets (Figure 3.4A).  Because lipid accumulation occurs during energy 
excess, we compared the ATP content of mono- and co-cultured HepG2 cells and found 
significantly higher ATP content in the co-cultured HepG2 cells (Figure 3.4B).  
Consistent with increased lipogenesis during co-culture, co-cultured HepG2 cells 
expressed higher mRNA levels of the lipogenic transcription factor, Pparγ, than mono-
cultured HepG2 cells (Figure 3.4C).  Co-culture also enhanced HepG2 expression of 
monocarboxylate transporter 1 (Mct1), which encodes a lactate transporter (Halestrap 
and Price 1999), but suppressed expression of pyruvate dehydrogenase kinase (Pdk1), 
which encodes an enzyme that gates entry of pyruvate into the tricarboxcylic acid (TCA) 
cycle (Figure 3.S3).  These findings suggest that malignant hepatocytes import MF-
derived lactate and convert it into pyruvate to fuel ATP and lipid biosynthesis.  To assess 
this issue more directly, we treated monocultured HepG2 cells with lactate in the 
absence or presence of FX11.  FX11 inhibits the activity of lactate dehydrogenase, 
thereby blocking the interconversion of lactate and pyruvate (Le, Cooper et al. 2010).  
Treating HepG2 cells with lactate significantly increased lipid accumulation and ATP 
content.  Both responses were prevented when cells were pre-treated with FX11 to 
inhibit intracellular conversion of lactate into pyruvate (Figure 3.4D).  Similar results were 
obtained when another hepatoma cell line, Huh7.5, was co-cultured with liver MF or 
treated directly with lactate (Figure 3.S4), providing reassurance that the findings were 
not restricted to a single liver cancer cell line. 
 The aggregate data, therefore, support a model whereby malignant hepatocytes 
generate HH-ligands to orchestrate the construction of a Hh-responsive stroma that 
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nurtures further growth of the malignant epithelia.  The cancer-associated process 
resembles epithelial-stromal interactions that are triggered by injury to nonmalignant liver 
epithelial cells.  When damaged, such cells begin to produce HH-ligands that also act in 
a paracrine fashion to promote accumulation of Hh-dependent MF (Omenetti, Choi et al. 
2011).  In nontumorous cirrhotic livers, MF are a major source of fibrous matrix, but also 
produce various factors that promote the survival of residual liver epithelial cells 
(Friedman 2008).  Here we identify end-products of Hh-dependent changes in MF 
metabolism as novel trophic factors for malignant hepatocytes by showing that Hh 
signaling in MF stimulates glycolysis, and demonstrating that malignant hepatocytes use 
MF-derived lactate to generate ATP and fuel lipogenesis (Figure 3.S5).  Evidence that 
the lactate-induced responses are blocked by treating malignant hepatocytes with an 
inhibitor of lactate dehydrogenase suggests that the improved epithelial energy balance 
occurs because malignant hepatocytes convert the assimilated lactate into pyruvate, 
which is then shunted into the TCA cycle to increase mitochondrial ATP production.  In 
HCCs, therefore, increased aerobic glycolytic activity (i.e., the Warburg effect) is an end 
result of collaborations between malignant hepatocytes and glycolytic MF in the tumor 
associated stroma.  Via this process, the malignant hepatocytes reap the benefits of the 
excess lactate generated by glycolysis without becoming glycolytic themselves, thereby 
fully retaining the capacity for oxidative phosphorylation and efficient ATP synthesis.  
Although this concept is contrary to conventional dogma which localizes the Warburg 
effect to the malignant cells themselves (Christofk, Vander Heiden et al. 2008), it is 
consistent with other recent reports of lactate production by stroma in breast cancer 
(Bonuccelli, Tsirigos et al. 2010), and raises the intriguing possibility that Hh-mediated 
switches in stromal cell metabolism also occur in cancers other than HCC.  In any case, 
evidence for increased glycolytic activity in tumor-associated MF has important 
diagnostic and therapeutic implications.  It suggests that positron emission tomography 
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(PET) scans might be deployed to identify HCC that are particularly enriched with 
glycolytic stroma.  The latter information might facilitate HCC detection, and could also 
have prognostic significance because highly glycolytic tumors tend to have more 
aggressive biology (Yeluri, Madhok et al. 2009).  Knowing which HCC are most enriched 
with glycolytic stroma would also justify, and help to refine, novel treatment approaches 
for HCC, supporting consideration of Hh inhibitors, LDH antagonists, and glycolysis 
inhibitors, as potential therapies for some patients with this life-threatening disease.   
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Figure 3.1. Evidence for paracrine Hedgehog signaling between malignant 
epithelia and tumor stroma in human HCC. 
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Figure 3.1. Evidence for paracrine Hedgehog signaling between malignant 
epithelia and tumor stroma in human HCC. Tumor and adjacent nontumorous liver 
from 5 patients with HCC were evaluated by immunohistochemistry (IHC) and 
quantitative morphometry.  Representative sections are shown and mean +/- SD 
morphometric data are graphed; *p<0.05 for tumor vs nontumorous tissue.  (A) SHH 
ligand (brown, 50x). Dotted lines enclose fibrotic capsule. (B) GLI2 (arrows, 400x) (C) 
PKM2 (brown) in non-tumor and tumor nodules (400x). (D) Co-localization of PKM2 
(green) with αSMA (brown) in tumor nodule (400x, 1000x insert). 
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Figure 3.2. Murine HCC stroma is enriched with Hh-dependent glycolytic MF.
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Figure 3.2. Murine HCC stroma is enriched with Hh-dependent glycolytic MF. Mdr2-
deficient mice with HCC were treated with the Hh-inhibitor, GDC-0449, or vehicle (N=5 
mice/group); effects on stroma of microdissected tumor nodules were evaluated by 
morphometry of immunostained sections and QRT-PCR.  Representative sections and 
mean +/- SEM data are displayed (*p<0.05, **p<0.01 GDC-0449- vs. vehicle-treated 
groups).  (A) Co-localization of PKM2 (green) with αSMA (brown) in tumor from vehicle-
treated mouse (400x). (B) QRT-PCR for Gli2, αSma, Glut1, Hk2, Pgk1 in liver tumor 
RNA. (C) Tumor sections from Vehicle- and GDC-0449 treated mice demonstrate (Top) 
PKM2, (Middle) αSMA, and (Bottom) MCT4 (brown, 200x) 
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Figure 3.3. Paracrine Hh signaling stimulates MF glycolysis.
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Figure 3.3. Paracrine Hh signaling stimulates MF glycolysis. (A) Gli-luciferase 
reporter activity in Shh–LightII cells incubated with control medium, 1000ng/mL 
recombinant SHH ligand,  co-cultured with HepG2 in a Transwell system, incubated with 
HepG2-conditioned media without or with 5E1 neutralizing antibody; (*p<0.05, **p<0.01).  
(B) Pkm2 and Mct4 RNA levels in  MFs grown in monoculture or co-cultured with 
HepG2s in Transwells.  (C) Intracellular (I.C.) lactate/pyruvate ratio in MFs mono-
cultured or co-cultured with HepG2 cells.  (D) Pkm2, Mct4, and Patched RNA levels in 
MFs grown in control-media or with HepG2-conditioned media (CM). (E) Pkm2, Mct4, 
and Patched RNA levels in MFs grown in HepG2-conditioned media (CM) without or with 
5E1 neutralizing antibody   (F) Pkm2 and Mct4 mRNA levels in MFs treated with Vehicle 
or recombinant SHH ligand (rSHH-L).  (G) Intracellular (I.C.) lactate/pyruvate ratio in 
MFs after treatment with rSHH-L.  (H) Lactate exported into media by MFs treated with 
control media, rSHH-L or rSHH-L+GDC-0449. Mean +/- SEM data from triplicate 
experiments are graphed; *p<0.05, **p<0.01 vs. respective controls. 
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Figure 3.4. Lactate generated by glycolytic MF fuels lipogenesis in HepG2 cells. 
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Figure 3.4. Lactate generated by glycolytic MF fuels lipogenesis in HepG2 cells. 
(A) Oil Red O staining of HepG2 cells grown alone or co-cultured in Transwells with MFs 
and quantified by morphometry. (B) Intracellular ATP and (C) MCT1, PPARγ, PDK1 
mRNA levels in HepG2 cells cultured alone or in Transwells with MFs. (D) Change in Oil 
Red O staining and ATP in HepG2s after treatment with 40mM lactate or FX11.  Mean 
+/- SEM data from triplicate experiments are graphed; *p<0.05, **p<0.01 vs. respective 
control 
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Figure 3.S1. Panc 10.05 cells do not generate functional Hh ligands (A) Gli-
luciferase reporter activity in Shh–LightII cells incubated with control medium (white bar), 
grown in co-culture with Panc 10.05 cells (gray bar), or incubated with Panc 10.05-
conditioned media (black bar).  (B) Ptc RNA levels in 8B MFs grown in monoculture 
(white bar), grown in co-culture with Panc 10.05 cells (gray bar), or incubated with Panc 
10.05-conditioned media (black bar).  (C) Pkm2 and Mct4 RNA levels in 8B MFs grown 
in monoculture (white bar) or in co-culture with HepG2 (grey bar) (*p<0.05, **p<0.01). 
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Figure 3.S2. Other malignant hepatoma lines can increase MF Hh and glycolytic 
activity. (A) Gli-luciferase reporter activity in Shh–LightII cells incubated with control 
medium (white bar), grown in co-culture with Huh7.5 cells (gray bar), or incubated with 
Huh7.5-conditioned media (black bar).  (B) Pkm2, Mct4, and Ptc RNA levels in 8B MFs 
grown in monoculture (white bar) or grown in co-culture with Huh7.5 cells (black bar). 
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Figure 3.S3. Summary of glycolytic metabolism. During glycolysis, glucose is 
converted to pyruvate, which can either be shunted to lactate via the enzyme lactate 
dehydrogenase (LDH) or taken into the tricarboxcylic acid (TCA) cycle after conversion 
into acetyl Co-A. Entry into the TCA cycle is regulated by the enzyme pyruvate 
dehydrogenase kinase. 
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Figure 3.S4. MF-derived lactate provides energy source for lipogenesis in other 
malignant hepatoma lines. (A) Oil Red O staining quantified by morphometric analysis 
(*p<0.05, **p<0.01), (B) Intracellular ATP and (C) MCT1, PPARγ mRNA levels in Huh7.5 
cells cultured alone (white bar), co-cultured with 8B MFs (black bar), or cultured alone 
and treated with 40mM of lactate (striped bar). 
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Figure 3.S5. Schematic of alterations in hepatoma cells due to release of 
metabolic end products by glycolytic MF. Hepatoma cells take up MF-derived lactate 
(denoted by blue circles) across the cellular membrane via the MCT1 lactate importer. 
Lactate is then converted to pyruvate via lactate dehydrogenase (LDH) and enters the 
TCA cycle, via a process that is gated by pyruvate dehydryogenase kinase (PDK1). 
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 CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1. Summary 
Hepatocellular carcinoma (HCC) is a common and deadly cancer with limited 
treatment options, creating a patient-driven need for more effective therapies.  Because 
the major risk factor for HCC is fibrosis and cirrhosis, primary liver cancer arises in the 
context of an impaired physiologic response to injury.  Patients with compensated liver 
cirrhosis have as much as a 5% annual risk for developing HCC, and HCC commonly 
recurs in cirrhotic livers after tumor ablation.  These observations suggest that the 
cirrhotic microenvironment promotes the outgrowth of malignant hepatocytes, but the 
mechanisms involved remain obscure.   
Cirrhosis results from dysregulated repair of liver injury, leading to the 
progressive accumulation of excessive fibrous matrix.  Our lab discovered that injury 
activates the normally dormant Hedgehog (Hh) signaling pathway in the liver.  The Hh 
pathway is an evolutionarily conserved signaling pathway that is activated when HH 
ligands bind to the Patched (PTC) receptor which is expressed on the surface of Hh-
responsive cells, resulting in eventual Hh signaling activity mediated by the GLI family 
transcription factors.  Liver injury dramatically increases local production of Hh ligands 
by multiple cell types, including PDGF/TGF beta-mediated induction of Hh ligand 
synthesis by hepatic stromal cells, as well as de novo synthesis of HH ligands by injured 
liver epithelial cells, (e.g. hepatocytes).  The release of HH ligands activates Hh pathway 
activity in responsive cells found in progenitor and stromal compartments, mobilizing 
them to repopulate and repair the liver.  In particular, Hh pathway activity regulates the 
transcription of factors that enhance the growth, viability and fibrogenic activity of liver 
myofibroblasts (MF).  Thus, injury-related activation of Hh signaling creates a Hh-rich 
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microenvironment that promotes hepatic MF accumulation, liver fibrosis, and HCC.   
As reviewed extensively in Chapter 1, dysregulated Hedgehog signaling can 
result in development of various cancers, either through ligand-independent 
mechanisms (i.e. Smoothened or Patched mutations), or ligand-dependent mechanisms 
(i.e. paracrine signaling between stromal cells and malignant epithelia).  In HCC, high 
levels of Hh pathway activity correlate with worse patient outcomes.  There is evidence 
for both dysregulated ligand-independent and ligand-dependent Hh signaling.  Sicklick et 
al. first discovered that Smoothened (Smo) hyperactivity in HCC tissue, possibly caused 
by a point mutation in Smo, correlates with tumor size and pharmacologic targeting of 
Hh signaling reduces proliferation of HCC cell lines.  However, Pereira et al. show PTC 
positive stromal cells surrounding the tumor, suggesting that high Hh signaling activity 
does not occur in malignant hepatocytes in vivo, but possibly contributes in a paracrine 
fashion.  Based on these pre-clinical and clinical observations, we postulated that 
sustained Hh signaling contributes to liver fibrosis and fibrosis-associated HCC.  The 
studies we report in Chapters 2 and 3 provide direct evidence that dysregulated 
paracrine Hh signaling results in HCCarcinogenesis.   
 
4.1.1 – Mdr2-/- mice as a model of HCC 
To test our hypothesis that sustained Hh signaling contributes to liver fibrosis and 
fibrosis-associated HCC, we treated a mouse model of chronic liver injury and HCC with 
a Hh pathway inhibitor.  In mice, Mdr2 encodes for P-glycoprotein, which is expressed by 
hepatocytes and permits the transport of phosphatidylcholine across the cannicular 
membrane into bile (Smit, Schinkel et al. 1993).  The absence of phospholipids in the 
bile fosters liver injury that manifests as early as two weeks of age.  These mice 
demonstrate consistently higher serum aminotransferase levels at every age, consistent 
with other evidence that Mdr2 deficiency provokes chronic hepatocyte injury.  As liver 
125 
injury continues, Mdr2-/- mice develop progressive hepatic fibrosis and between 50 to 60 
weeks of age, HCCs spontaneously arise, making Mdr2 knockout mice a good model for 
fibrosis-induced HCC.  Similar to acute and chronic models of liver injury, Hh signaling is 
activated in Mdr2-/- mice and increases with time.  Therefore, aged Mdr2-/- mice with 
HCC mirrors the clinical presentation of HCC in older patients with a history of chronic 
liver disease, fibrosis, and cirrhosis.   
 
4.1.2 – Inhibition of Hedgehog signaling in aged Mdr2-/- mice 
High levels of Hh signaling in aged Mdr2-/- mice led us to hypothesize that 
treatment with a direct antagonist of Smoothened, GDC-0449 (reviewed in Chapter 1.6), 
would provide substantial disease improvement.  We validated GDC-0449 treatment by 
examining its effect on Hh signaling.  Using markers for Hh signaling activity (Gli2, Gli1, 
Pparγ), we noticed a significant decrease in Hh activity after treatment both in non-tumor 
liver parenchyma and within the tumor nodule.  To evaluate the impact of Hh signaling 
inhibition, pre- and post-treatment tumor volumes were analyzed by magnetic resonance 
imaging (MRI).  After 9 days of treatment, vehicle treated animals evidenced persistent 
tumor growth, while mice that received GDC-0449 treatment demonstrated decreased 
tumor volume (22.7% ± 9.1% versus -6.7% ± 11.7%).  These data were consistent with 
necropsy findings: 80% of vehicle treated mice had visible liver tumors compared with 
only 56% of GDC-0449 treated mice.  Histological analysis of tumor nodules also 
revealed decreased rates of hemorrhagic infarcts, acidophilic necrosis and degenerative 
cytoplasmic changes, and microvesicular steatosis.  All three methods used to analyze 
tumor burden in Mdr2 KO mice following treatment consistently demonstrated significant 
tumor regression.  Furthermore, both MRI and necropsies showed a decreased number 
of metastatic lesions in GDC-0449 mice, compared to vehicle treated mice.  Thus, the 
prohibitive effect on hepatic tumor growth in vivo pertains to both intra-hepatic HCC and 
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distant metastasis.  Excitingly, this is the first documented in vivo evidence that Hh 
signaling inhibition has potential therapeutic benefit against HCC.  Since our publication, 
another group has shown that knockdown of Hh signaling through inhibition of GLI1 in 
vivo reduces tumor burden in subcutaneous and orthotopic xenograft HCC models, 
providing additional evidence for targeting Hh signaling as a viable strategy to treat HCC 
(Xu, Chenna et al. 2012). 
 
4.1.3 – Impact of Hh signaling inhibition on progenitor populations of aged Mdr2-/- mice 
Since liver injury causes Hh-responsive liver progenitors to proliferate and 
contribute to carcinogenesis, we asked whether these populations would be affected by 
Hh signaling inhibition.  Hh-responsive progenitors, marked by CK-19 and AFP, showed 
significant decreases after treatment, suggesting that Hh signaling is required to 
maintain progenitor populations even in mice with advanced HCC.  The tumor 
environment is also thought to be populated with CD44 positive cells, a receptor for the 
stem cell growth factor and immunomodulator osteopontin (OPN).   Treatment with 
GDC-0449 significantly decreased OPN expression within the primary tumors and a 
similar decrease in CD44 positive cells were also noted, suggesting that Hh signaling 
may regulate liver progenitor cells by modulating availability of OPN.  In this regard, Xu 
et al. also observe, following in vivo inhibition of Hh signaling in their models of HCC, 
significant decreases in liver progenitors  (Xu, Chenna et al. 2012).  
 
4.1.4 – Loss of tumor volume in GDC-0449 treated Mdr2-/- mice is accompanied by a 
reduction in fibrosis 
 Unlike the xenograft models used by Xu et al., Mdr2-/- mice progressively 
accumulated liver MF and developed liver fibrosis, allowing us to study a model that 
parallels the natural evolution of HCC on a background of chronic inflammation, liver 
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injury and fibrosis.  Hh inhibition resulted in significantly reduced hepatic expression of 
alpha smooth muscle actin (a marker for liver MF) and fibrosis, suggesting that 
sustained Hh signaling is also required to maintain and expand populations of liver MF 
and sustain fibrogenic repair.  Reductions in the expression of other pro-fibrogenic and 
MF growth factors such as Tgf-β and Pdgf-β reinforce the effects of canonical Hh 
signaling on fibrogenic repair.  Osteopontin can also act as a pro-fibrogenic, factor and 
promotes MF accumulation (Syn, Choi et al. 2011).  Thus, loss of tumor volume was 
accompanied by reduction in fibrosis and cells that participate in fibrogenic repair.  While 
these results, discussed in Chapter 2, do not directly imply that fibrosis causes HCC, the 
observations form the basis of our hypothesis for our studies in Chapter 3, that the 
tumorigenicity of malignant hepatic epithelial cells is affected by factors generated by 
Hh-responsive liver MF. 
 
4.1.5 – Paracrine Hedgehog signaling in human HCC 
In injured livers, wounded liver epithelial cells are a major source of Hh ligands.  
In a paracrine fashion, these ligands then activate Hh signaling in nearby Hh-responsive 
cells, which include liver MF.  Because HCCs develop out of cirrhotic livers, we 
hypothesized that a similar paracrine mechanism between malignant hepatocytes and 
liver MF is possible.  To localize Hh ligand expression in HCC, we performed 
immunohistochemistry for Sonic Hedgehog (SHH) in archived paraffin-embedded 
tissues from 5 patients with HCC and cirrhosis caused by nonalcoholic fatty liver disease 
(NAFLD).  All of the HCCs demonstrated increased expression of SHH ligands relative 
to adjacent capsular tissue and non-tumorous liver.  Furthermore, within the tumor 
nodule, as in injured livers, the main source of SHH ligands are from the hepatocytes.  In 
contrast, nuclear staining for the Hh-regulated transcription factor, GLI2, was confined to 
the tumor-associated stroma, which was significantly enriched with GLI2(+) stromal cells 
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compared to adjacent non-tumorous liver.  These results demonstrate that malignant 
epithelia in the liver are not Hh responsive but produce HH ligands that activate Hh 
signaling in Hh-responsive stromal cells.  This system of ligand-dependent paracrine Hh 
signaling is congruent with observations in other cancers, most notably in pancreatic 
cancer, and has been shown in vitro (Yauch, Gould et al. 2008) and in vivo (Bailey, Mohr 
et al. 2009). 
 
4.1.6 – Human HCC harbors glycolytic liver myofibroblasts 
Observations of paracrine signaling between malignant hepatocytes and Hh-
responsive stromal cells in HCC led us to question the benefits of a collaborative 
relationship between these two cell types.  Again we turned to injured livers to form the 
framework for our hypothesis.  Other work in our lab indicates that Hh-responsive MF in 
fibrotic livers express pyruvate kinase M2 (PKM2), a well-established marker of 
glycolytic activity (Chen, Choi et al. 2012).  During liver fibrogenesis, most MF are 
derived from resident hepatic stellate cells (HSC). Our lab has recently shown that 
paracrine Hh signaling can induce HSC to become proliferative and myofibroblastic 
(Rangwala, Guy et al. 2011) and this process is mediated by glycolysis (Chen, Choi et 
al. 2012).  Given that localization of glycolytic cells in the pre-neoplastic liver is limited to 
the stromal compartment, we wanted to access glycolytic activity in HCC.  We found that 
PKM2 staining also localized to cells within HCC stroma (rather than to the malignant 
hepatocytes themselves) in human samples and showed that human HCC stroma 
harbored greater numbers of glycolytic cells than adjacent nontumorous liver.  Dual 
staining for PKM2 and GLI2 confirmed that these glycolytic stromal cells are Hh-
responsive.  Finally, expression of PKM2 co-localized with ASMA in human HCC, 
demonstrating that glycolytic tumor-associated stromal cells are Hh-responsive MF.  
Over 80 years ago, Otto Warburg noted that the growth of many cancers and other 
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highly proliferative cells relies upon glycolysis, even when sufficient oxygen is available 
for oxidative phosphorylation, a phenomenon dubbed the Warburg Effect (Warburg 
1956).  Our findings in a small cohort of NAFLD-associated HCC introduce novel 
evidence that this phenomenon occurs in HCC-associated MF, rather than the malignant 
hepatocytes. 
 
4.1.7 – Hh inhibition in aged Mdr2-/- mice reduces glycolytic activity in HCC tumor 
nodules 
In the Mdr2-/- mouse model of HCC, the stromal compartment is also enriched 
with glycolytic MF that are Hh responsive.  To examine the role of Hh signaling in 
regulating glycolytic activity in the HCC-associated MF, we compared expression of 
Glut1, a glucose transporter, and several key glycolytic enzymes in mRNA isolated from 
HCCs of Mdr2-deficient mice treated with either vehicle or GDC-0449.  Treatment with 
the Hh inhibitor reduced expression of mRNAs encoding Glut1 and other glycolytic 
enzymes (Figure 3.2B).  Reduced expression of MF- and glycolysis-associated mRNAs 
was paralleled by depletion of tumor stromal cells that expressed ASMA and PKM2.  
These results suggested to us that Hh signaling mediates the glycolytic potential of 
stromal MF in the tumor microenvironment. 
 
4.1.8 – Malignant hepatocytes secrete HH ligands which enhance glycolytic activity in 
liver MF 
Given these observations, we hypothesized that liver MF glycolysis might have 
been induced in a paracrine fashion by Hh ligands generated by the malignant hepatic 
epithelial cells.  To test this hypothesis, we first needed to determine if malignant 
hepatocytes could generate HH ligands in vitro.  To this end, we exposed Shh-LightII 
cells, a clonal 3T3 cell line stably incorporating a Gli-responsive firefly luciferase 
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reporter, to soluble factors from malignant hepatocytes (HepG2 cells).  Similar to their 
exposure to recombinant SHH (rSHH) ligand, exposure to HepG2 cell-derived soluble 
factors significantly increased Hh signaling in the Shh-LightII cells.  The stimulatory 
effect of HepG2 conditioned medium was abrogated by adding 5E1, a Hh neutralizing 
antibody that blocks HH ligand-PTC interaction, further suggesting that paracrine 
interaction involving malignant hepatocyte-produced HH ligands drive Hh signaling in 
neighboring Hh responsive cells.  To determine if these HepG2-derived factors directly 
functioned as inducers of MF glycolysis, we exposed a well-characterized rat liver MF 
line (8B cells) to HepG2 cells products, either directly in co-culture or indirectly with 
HepG2 conditioned media, and assessed MF glycolytic activity.  Compared to growth in 
monoculture, exposure of MF to HepG2-derived factors increased several markers of 
MF glycolytic activity, including increasing the lactate to pyruvate ratio.  The stimulatory 
effects of HepG2-conditioned medium on MF glycolysis were attenuated by adding 5E1 
antibody, suggesting that HH-ligands are the factors that malignant hepatocytes release 
to induce glycolytic activity in neighboring MF.  To verify that paracrine activation of Hh 
signaling in MF promotes glycolysis, we treated liver MF with rSHH ligand and found 
similar increases in glycolytic activity.   GDC-0449 reversed the effects of rSHH-ligand, 
confirming that MF glycolysis is Hh-dependent.   
 
4.1.9 – Liver MF secrete glycolytic end products which promote lipogenesis in malignant 
hepatocytes 
Several groups studying breast cancer and ovarian cancer have suggested that 
resident stroma in the tumor microenvironment release metabolic end-products that 
influence the growth and invasion of malignant epithelia.  As we discussed in Chapter 1, 
lactate is one such metabolite that promotes tumorigenicity.  Immunohistochemistry in 
Mdr2-/- mice for monocarboxylate transporter 4 (MCT4), a lactate exporter, shows the 
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same stromal pattern as ASMA and PKM2 staining, suggesting that stromal MF in HCC 
export lactate.   Both in vivo and in vitro data demonstrate that Hh signaling regulates 
MF secretion of lactate: 1) Treatment of Mdr2-/- mice with the Hh inhibitor reduced 
MCT4 expression, and 2) Adding rSHH to liver MF media significantly increased their 
secretion of lactate into the media, while including GDC-0449 decreased media lactate 
below basal levels.  Because of these results, we hypothesized that the tumorigenicity of 
malignant hepatic epithelial cells is supported by liver MF-generated end-products of 
glycolytic metabolism, specifically lactate. 
In vitro and in vivo models of lactate treatment demonstrate that lactate promotes 
lipogenesis (Palacin, Lasuncion et al. 1988; Tabernero, Vicario et al. 1996; Sanchez-
Abarca, Tabernero et al. 2001).  In multiple cancers including breast (Zhang, Tai et al. 
2005), prostate (Dhanasekaran, Barrette et al. 2001; Rossi, Graner et al. 2003), lung 
(Visca, Sebastiani et al. 2004; Migita, Narita et al. 2008), ovarian (Gansler, Hardman et 
al. 1997; Alo, Visca et al. 2000), and liver (Calvisi, Wang et al. 2011), a lipogenic 
phenotype is associated with poorer prognosis.  To evaluate the related hypothesis that 
MF-derived glycolytic end-products enhance net energy homeostasis of malignant 
hepatocytes, we co-cultured malignant hepatocytes with liver MF.  Compared to 
monocultured HepG2 cells, HepG2 cells in co-culture demonstrated significant 
accumulation of Oil Red O-stained lipid droplets and expressed higher mRNA levels of 
the lipogenic transcription factor, Ppar, suggesting that MF factors increased 
lipogenesis.  Because lipid accumulation occurs during energy excess, we compared the 
ATP content of mono- and co-cultured HepG2 cells and found significantly higher ATP 
content in the co-cultured HepG2 cells.  Co-culture enhanced the HepG2 expression of 
monocarboxylate transporter 1 (Mct1), which encodes a lactate importer, but suppressed 
expression of pyruvate dehydrogenase kinase (Pdk1), an enzyme that gates the entry of 
pyruvate into the tricarboxcylic acid (TCA) cycle.  These findings suggest that malignant 
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hepatocytes import MF-derived lactate to fuel ATP and lipid biosynthesis.  To address 
this question more directly, we treated HepG2 cells with lactate in the absence or 
presence of a lactate dehydrogenase (LDH) inhibitor.  Treating HepG2 cells with lactate 
significantly increased lipid accumulation and ATP content and both responses were 
prevented when cells were pre-treated with the LDH inhibitor. 
 
4.1.10 – Paracrine Hedgehog signaling within the HCC tumor could explain clinical 
observations about HCC progression 
Our results demonstrate that crosstalk between stromal liver MF in the tumor 
microenvironment and malignant hepatic epithelial cells are regulated by paracrine 
Hedgehog signaling, which ultimately can alter the metabolic profile of the tumor and 
drive lipogenesis.  These results are fascinating in light of clinically relevant observations 
that HCCs, and specifically malignant hepatocytes, undergo a fatty metamorphosis.  In 
the earliest documentation of this phenomenon, needle biopsy specimens were taken 
from a patient with HCC and over the course of 18 months, the authors observed 
progressive fatty metamorphosis in well-differentiated tumor cells (Chan and Ma 1975).  
Since then, using a variety of imaging techniques and a larger number of patients, there 
have been several clinical reports confirming fatty metamorphosis in HCC throughout the 
progression of the disease (Isomura and Nakashima 1980; Yoshikawa, Matsui et al. 
1988; Tsunetomi, Ohto et al. 1989; Martin, Sentis et al. 1995).  In a bioinformatics 
analysis of tumors from Mdr2-/- mice, compared to normal mouse livers, genes regulating 
lipogenesis and fatty acid synthesis such as fatty acid synthase (fasn) and fatty acid 
binding protein 4 (fabp4) were upregulated 2.6 and 13.64 fold, respectively, which 
suggests that increased lipogenic activity in HCC tumors is not species-specific 
(Katzenellenbogen, Mizrahi et al. 2007).  These same lipogenesis-associated genes are 
elevated in human HCC and associated with worse clinical outcomes (Yamashita, 
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Honda et al. 2009).  Furthermore, the functional connection between lipogenesis and 
increased proliferation and survival in HCC cells has been established (Calvisi, Wang et 
al. 2011), and that suppression of lipogenesis reduces these malignant phenotypes 
(Bhalla, Hwang et al. 2012).  Our study provides the first evidence that liver MF within 
the tumor microenvironment can contribute to these fatty changes.    
 
4.2. Future Directions 
As with any scientific inquiry, new answers raise new questions.  Based on our 
understanding of dysregulated Hedgehog signaling in injured livers, we postulated that 
Hedgehog signaling contributes to the pathogenesis of hepatocellular carcinomas.  
Paracrine Hedgehog signaling between HH ligand producing malignant hepatocytes and 
Hh-responsive liver MF alters the cellular metabolism of both cell types.  But one 
immediate question that arises: What mechanisms regulate malignant hepatocyte 
production of HH ligands? 
Answers to this question have broad clinical implications.  If malignant 
hepatocytes use HH ligands to communicate with their stromal neighbors, localizing the 
stimulus for the production of HH ligands may provide new therapeutic avenues.  
Despite not expressing much Hh associated activity, malignant hepatocytes secrete high 
levels of HH ligands, suggesting that HH ligand production is not always regulated by 
intracellular Hh signaling.  In Chapter 3, we focused on one aspect of the reciprocal 
relationship between liver MF and malignant hepatocytes, and in particular, how 
malignant hepatocytes stimulate liver MF to release tumorigenic metabolites.  Crosstalk, 
however, can occur in both directions.  When cultured with conditioned media from 
malignant hepatocytes, Shh-LightII cells express less Hh signaling activity than when co-
cultured with malignant hepatocytes (Figure 3.3A).  This piece of data suggests that 
fibroblast-derived factors can stimulate malignant hepatocytes to increase secretion of 
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HH ligands.  Thus, a reasonable hypothesis would predict that products of liver MF 
stimulate malignant hepatocytes to release HH ligands.  In Chapter 2, after treating 
Mdr2-/- mice with a Hh inhibitor, we observed decreased tumor burden and fibrosis.  
Because liver MF are the main producers of fibrous matrix in the injured liver, one area 
that remains open for investigation is how malignant hepatocytes respond to 
extracellular matrix (ECM) remodeling by liver MF. 
 
4.2.1 – The role of extracellular matrix in HCC 
The influence of ECM on HCCarcinogenesis is a nascent and recent area of 
investigation.  ECM structural integrity and stiffness is maintained, in part, by collagen 
fibers secreted by liver MF (de Leeuw, McCarthy et al. 1984; Kolacna, Bakesova et al. 
2007).  Since the early 2000s, clinical evidence for a relationship between ECM and 
HCC has emerged.  The first study analyzed levels of ECM remodeling in patients, 
determined by collagen I and metalloproteinase activity, and correlated increased ECM 
remodeling with greater tumor recurrence (Theret, Musso et al. 2001).  Similarly, a later 
study of 106 HCC patient samples found that greater ECM mechanical stiffness 
correlates with a more invasive and metastatic HCC phenotype (Zhao, Cui et al. 2010).    
A prospective study involving 866 patients demonstrated that increased ECM stiffness, 
as measured by transient ≥ 10 kPa; 95% CI, 9.75-212.3; P < 0.001) for developing HCC 
(Masuzaki, Tateishi et al. 2009).  At an in vitro level, increasing ECM stiffness increases 
the proliferative and cisplatin-resistant capacity of malignant hepatocyte cell lines 
(Schrader, Gordon-Walker et al. 2011). 
 
4.2.2 – Integrins: How cells experience the world 
The ability for cells to sense and process environmental cues, such as changes 
in the ECM, is mediated by a family of cell surface receptors called integrins (Miranti and 
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Brugge 2002).  Integrins are essential for both cell-cell and cell-matrix interactions 
(Hynes 1987).  Stimulation of integrins and subsequent signal transduction relies on 
binding of integrin receptors to ECM proteins (Hanks, Calalb et al. 1992).  This action 
recruits the tyrosine kinase, focal adhesion kinase (FAK), which itself is auto-
phosphorylated to become FAKPY397, and further propagates integrin signal transduction.  
Given early observations that tumors result from faulty wound healing (i.e. dysregulated 
ECM deposition), it is no surprise that integrin signaling has been implicated in cancer 
development.  Breast cancer cells that form invasive colonies with disrupted polarity and 
exhibit uninhibited growth all have enhanced integrin signaling (Paszek, Zahir et al. 
2005).  Furthermore, inhibition of integrin signaling restores tissue polairity and 
downregulates malignant behavior.  Intriguingly, the Pasek et al. saw that ECM stiffness 
also returns to baseline with integrin signaling inhibition, suggesting malignant epithelia 
and ECM reciprocally act on each other.  Additional links between fibroblasts, ECM, and 
malignancy have been developed.  Mouse mammary fat pads preconditioned with 
fibroblasts programmed to produce more collagen crosslinks (i.e. increasing ECM 
stiffness) permit the growth of more invasive and proliferative tumors (Levental, Yu et al. 
2009).  These authors further demonstrate that integrin signaling in malignant epithelial 
cells requires an appropriate level of ECM stiffness to promote malignant behaviors and 
this signaling is reliant on PI3K-AKT activity.  Previous studies have also shown that 
integrin signaling can regulate PI3K activity in non-malignant settings (Chen, Appeddu et 
al. 1996). 
 
4.2.3 – Integrins and HCC 
In the study by Levental, breast cancer progression from a non-malignant to 
malignant environment relied on fibroblast-mediated ECM remodeling and integrin-
driven PI3K activity in malignant epithelia.  Given the interplay between dysregulated 
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wound healing, liver MF production of ECM components (e.g. collagen), and HCC 
development, these results raise the compelling possibility that a similar mechanism and 
model could exist in HCC.  Since type I and IV collagen are the major ECM components 
of fibrotic and cirrhotic liver tissue, it is no surprise that α1 and α2 subunits of β1 integrin, 
subunits that bind collagen, are highly elevated in malignant hepatocytes (Yang, 
Zeisberg et al. 2003) and are required for migration through and adhesion to the ECM 
(Torimura, Ueno et al. 2001).  Two studies also observed high expression of β1 integrin 
within HCC tumor nodule in human patients, specifically within malignant hepatocytes 
and not sinusoidal cells (Zhao, Cui et al. 2010; Schrader, Gordon-Walker et al. 2011).  In 
the study by Schrader et al., HCC cells grown on stiffer matrices not only exhibited 
increased proliferation and epithelial disruption, but also showed increased expression of 
phospho-AKT.  In vitro pharmacologic targeting of FAKPY397, a key mediator of integrin 
signaling, diminished the proliferative advantage of malignant hepatocytes growing on 
stiff matrices, providing further evidence these phenotypic changes are facilitated by 
integrin signaling.  These results are supported by a complementary study 
demonstrating that increased ECM stiffness in vitro directly results in increased β1 
integrin mRNA in HCC cell lines (Zhao, Cui et al. 2010).  
 
4.2.4 – A conceivable role of extracellular matrix in HCC 
Taken together with the clinical observations, the in vitro experiments support a 
hypothesis that malignant hepatocytes sense and respond to changes in ECM through 
integrin signaling.  Additional evidence is needed to establish whether: a) liver MF 
remodeling of ECM can induce tumorgenic changes in malignant hepatocytes, and b) 
the activation of integrin signaling in response to ECM changes is essential for HCC 
progression in vivo.  The link between integrin signaling and PI3K-AKT activity is 
especially intriguing because of the relationship between PI3K-AKT signaling and the 
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production of HH ligands.  In a study by Androutsellis-Theotokis et al., the authors 
showed that SHH ligand production was downstream of PI3K-AKT activation and 
regulated by mTOR/STAT3 signaling (Androutsellis-Theotokis, Leker et al. 2006).  
Furthermore, two groups have shown that pharmacologic treatment of HH-ligand 
expressing cells with an AKT inhibitor resulted in diminished production (Yang, Wang et 
al. 2008; Ramirez, Singh et al. 2012).  These cumulative studies help us refine our initial 
hypothesis that the secretion of HH ligands by malignant hepatocytes is in response to 
liver MF signaling.  By activating integrin signaling in response to ECM remodeling by 
liver MF, we can hypothesize that malignant hepatocytes stimulate a PI3K-AKT signaling 
cascade leading to increased production of HH ligands.  The net result would create a 
HH-rich microenvironment that promotes further fibrosis and secretion of tumorigenic 
molecules (e.g. cytokines, ligands, and growth factors).  If the hypothesis holds true, the 
results would add more evidence in support of anti-fibrotic agents as potential therapies 
for patients with HCC as well as inhibitors targeting the PI3K-AKT pathway.  Co-culture 
of liver MF with HepG2 cells results in increased β1 integrin expression in HepG2 cells, 
suggesting that malignant hepatocytes utilize integrins in response to factors produced 
by liver MF (Figure 4.1).  
 
4.2.3 – Other potential reasons for increased HH ligand production 
Other possibilities for increased production of HH ligands by malignant 
hepatocytes could simply be due to dysregulated Hh signaling.  SHH ligand is a 
downstream target of Hh signaling in some models of cancer (Clement, Sanchez et al. 
2007).  Both HCC specimens and HCC cell lines have been found to have elevated 
levels of Hh signaling (Huang, He et al. 2006; Sicklick, Li et al. 2006).  Furthermore, 
levels of Smoothened (Smo) expression showed a positive correlation with tumor size 
and a novel point mutation of Smo was identified in one patient, suggesting that 
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persistent  Smo activity can lead to dysregulated tumor growth (Sicklick, Li et al. 2006).   
However, both studies analyzed whole HCC tissue, which does not account for the 
heterogeneity of cells within the HCC tissue.  The lack of positive GLI2 staining in 
malignant hepatocytes from patients with NAFLD-induced cirrhosis and HCC suggests, 
along with observations that several HCC cell lines are unresponsive to Hh signaling 
inhibition, that not all malignant hepatocytes have dysregulated Hh signaling despite 
their production of HH ligands.  Although observations of ligand-independent and ligand-
dependent modes of Hh signaling seem to differ in HCC, this discrepancy is not unique 
to liver cancer; studies in prostate and pancreas cancers also have divergent results 
(Thayer, di Magliano et al. 2003; Karhadkar, Bova et al. 2004; Tian, Callahan et al. 
2009).  These differences merely emphasize the need for additional research to 
understand the circumstances when Hh signaling is intrinsically dysregulated in 
malignant hepatocytes and whether this dysregulation can lead to increased HH ligand 
production.  Finally, as mentioned above, PI3K signaling can regulate HH ligand 
production and dysregulation of this signaling pathway in malignant hepatocytes (Lee, 
Soung et al. 2005) could be the primary cause of HH ligand overproduction. 
 
4.3 – A student’s perspective on the “War on Cancer” 
By signing the National Cancer Act into law on December 23, 1971, President 
Richard Nixon made finding a cure for cancer a national effort and cultivated hope that 
this disease was as mortal as any human.  This goal of finding a cure was christened by 
media outlets as a national declaration of “war” against cancer.  And many people, 
scientists and non-scientists alike, were optimistic for a quick cure: In 2003, Andrew von 
Eschenbach, then the director of the NCI, vowed that we would “eliminate [the] suffering 
and death” caused by cancer by 2015.  All it would take to eradicate cancer was the right 
amount of organization and resources and the focus of our country’s top scientists.  
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These efforts have not been hindered by a lack of funding: Since 1971, we have 
invested $105 billion to understand what makes the enemy tick and how to stop the 
ticking.   
Beginning in the 19th century, when Rudolf Virchow first advanced cellular 
derivation as the source of cancers, we have dedicated much of our attention on the 
individual tumor cell.  And after the discovery of DNA, we could fully appreciate that the 
dysregulation of certain genes and their pathways lead to the oncogenic behavior of 
tumor cells.  It is undeniable that chemotherapies based on this understanding led us to 
formulate new and better treatments for patients.  We have moved from using nitrogen 
mustard (Goodman, Wintrobe et al. 1946) and folic acid antagonists (Farber and 
Diamond 1948) as potential treatments to targeted therapies such as imatinib (Druker, 
Guilhot et al. 2006).  Yet despite the progress the field has made, cancer has overtaken 
cardiovascular disease as the leading cause of death worldwide (World Health 
Organization 2012).  After adjusting for age and size of the population, from 1950 to 
2005 the death rate for cancer has dropped 5%, whereas during this same period, the 
death rate for cardiovascular diseases has dropped 64% (Kolata 2009).  In fact, in 2011, 
the 5-year mortality trend for pancreatic and liver cancer has even increased (Marshall 
2011).  These numbers have led several to question whether the war could be won at all 
(Bailar and Gornik 1997), whether we should focus on cancer prevention and detection 
(Lyman 2009), whether we need to develop more efficient ways to tailor chemotherapies 
(Chan and Ginsburg 2011), or whether our approach to drug development (Rubin and 
Gilliland 2012) and preclinical models (Ocana, Pandiella et al. 2011) is flawed.   
Strikingly, only 5% of agents identified as potential anticancer compounds in the 
preclinical setting make it past phase III trials (Kola and Landis 2004). Worse, 
compounds that are approved for clinical care often face high recurrence rates and offer 
medium effectiveness at improving survival (Begley and Ellis 2012).  While there is no 
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doubt that cancer care has enormously improved, mortality statistics contends that more 
can be done.  The first of several steps must be to improve preclinical models used to 
validate potential anticancer compounds.  Our in vitro models are limited to poorly 
annotated and sometimes highly passaged malignant epithelial cell lines (e.g. NCI-60 
lines).  Even primary cell lines developed from patients do not necessarily provide an 
accurate representation of the molecular heterogeneity of human tumors, nor do they 
fully recapitulate how malignant epithelia exist in situ.  These models lack the dimension, 
matrix support, and cell-to-cell interactions that cells normally experience in vivo.  Nor do 
they account for environmental cues like exposure to environmental stressors and 
hypoxia.  Unfortunately, animal models such as tumor xenografts are still tumor cell 
driven and are limited as well; the stromal component comprised entirely of host cells 
and these animals are often immunocompromised, making it difficult to assess the 
impact of the immune system on tumor development and treatment.  For example, 
Sorafenib, despite its ability to inhibit growth and angiogenesis in xenograft models of 
HCC and induce cellular apoptosis in HCC cell lines (Liu, Cao et al. 2006), was only able 
to extend average survival by three months in human patients.  While this was a 
significant breakthrough in treatment of HCC patients, the need for better treatments 
remains. 
Stromal cells and extracellular matrix components provide growth and survival 
signals to the tumor cell in a capacity that we are only beginning to discover.  Our results 
contribute to a burgeoning body of literature that chronicles how the network of stromal 
cells and tumor cells promote malignant phenotypes and spawn an environment that 
nurtures tumorigenesis.  The data suggest that it is time to move beyond a tumor cell-
based approach to cancer research.  Instead of reducing and eliminating complexities in 
our model, we need to take a holistic, systems biology approach to understanding how 
tumors work.  Models therefore ought to be 1) sensitive, 2) specific, 3) reproducible, 4) 
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tractable, 5) scalable, and 6) affordable.  Currently, although many of these models are 
highly sensitive (low false negative rates), they are not very specific (high false positive 
rates) nor are they always reproducible at the clinical level.  Genetically engineered 
mouse models are effective and adaptable systems to assess transformation events and 
microenvironment contributions to cancer.  They are immune competent, so they retain a 
crucial component of tumor response.  Yet they are expensive and the molecular 
alterations that often generate tumors are limited and artificial (as compared to the 
spontaneous emergence of human tumors and their heterogeneous compositions), 
making them still imperfect models (Olive and Tuveson 2006).  Our analysis of these 
models also requires broadening: Bioinformatics should be harnessed to account for 
intercellular communications instead of limiting analysis to intracellular genomic 
information (Gentles and Gallahan 2011).  Antitumor compounds need to be evaluated 
in in vitro and in vivo models that accurately represent how tumors propagate and persist 
in humans.  Damage signals from injured stroma have been shown to actually promote 
tumor drug resistance and survival, suggesting that cytotoxic chemotherapy may have 
unanticipated effects (Sun, Campisi et al. 2012).  Failure to account for stromal cells 
during drug development might be a cause of why we observe drug resistance and a 
combinational approach may be required to target both stromal and tumor compartments 
(Olive, Jacobetz et al. 2009). 
Traditionally, funding for riskier ideas has not always been available.  Economic 
incentive needs to be shifted to spur scientists towards inventing truly novel models that 
addresses the limitations of our current ones.  But while it is easy to remain critical at the 
perceived infancy of effective clinical treatments against different cancers (Bailar and 
Gornik 1997), it is also important to remember that scientific progress, especially those 
that lead to effective therapies, results from decades of incremental research.  As 
Thomas Kuhn states in The Structure of Scientific Revolutions, “The success of a 
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paradigm…is at the start largely a promise of success discoverable in selected and still 
incomplete examples.”  Changes in scientific thought can occur only through what, on 
the surface, must seem to be disjointed examples and slow moving progress.  Bold 
scientific thought takes a great deal of time and investment to rigorously test and an 
even greater commitment to develop clinical strategies based on these ideas.  A 
reminder of this fact is the 30-year story of the chemotherapy paclitaxel, which began in 
1962 with the collection of tree bark, entered phase I clinical trials in 1984, and was 
finally approved for clinical use in 1992 (Goodman and Walsh 2001).  More work is 
required and superior models need to be established, but we are steadily traversing into 
a new paradigm where our understanding of cancers will be expanded to include all the 
cells within the tumor.  Stephen Paget, the distinguished English surgeon credited for 
proposing the seed and soil theory of cancer, observed over a century ago that cancers 
require both the tumor cell and a suitable microenvironment for growth.  His advice, that 
“properties of the soil may also be useful”, still holds true 123 years later. 
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Figure 4.1.  Coculture with liver MF increases β1-integrin expression in 
HepG2 cells.  As compared to HepG2 cells in monoculture (MC), HepG2 cells in co-
culture with liver MF (CC) express a 3-fold increase in β1-integrin expression. 
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